

HEALTH ANNUAL STATEMENT

AS OF DECEMBER 31, 2019 OF THE CONDITION AND AFFAIRS OF THE

Aetna Better Health Inc. (a New Jersey corporation)

	Ctild Detter	i icaitii iiici (a item ocio	cy corpore	ition,
NAI	C Group Code 0001 (Current)	0001 NAIC Company	Code 15611 Emplo	oyer's ID Number 4	6-3203088
Organized under the Laws of			, State of Domicile or Por	t of Entry	NJ
Country of Domicile		United Sta	tes of America		
Licensed as business type:		Health Mainter	ance Organization		<u>.</u>
Is HMO Federally Qualified?	Yes[] No[X]				
Incorporated/Organized	05/01/201	13	Commenced Busine	ss	01/01/2015
Statutory Homa Office	3 Independence	Way Suite 400		Princeton, NJ, US	08540
Statutory Home Office	(Street and	·		City or Town, State, Count	
Main Administrative Office		3 Independen	ce Way, Suite 400		
•	D: 1 NI 21D 00540	(Street a	ind Number)	055 000 056	ne.
(City o	Princeton, NJ, US 08540 r Town, State, Country and Z	in Code)		855-232-359 (Area Code) (Telephor	
(Oity o	r Town, State, Country and 2	ip Gode)		(Alex Oode) (Telephol	ic (validar)
Mail Address	1425 Union Meeting F			Blue Bell, PA, US	
	(Street and Number o	r P.O. Box)	, (0	City or Town, State, Count	ry and Zip Code)
Primary Location of Books ar	nd Records	3 Independer	ice Way, Suite 400		
	Di	(Street a	nd Number)	055 020 256	ne.
(City o	Princeton, NJ, US 08540 r Town, State, Country and Z	in Code)		855-232-359 (Area Code) (Telephor	
, -				Ç, ()	· · · · · · · · · · · · · · · · · · ·
Internet Website Address		www.aetna	petterhealth.com		
Statutory Statement Contact	C	ara Sue Mullen		215-77	
Δ	etna.HMOReporting@aetna.c	(Name)		(Area Code) (Tele 860-262-776	•
	(E-mail Address)	50111		(FAX Number	
		OFF	ICERS		
	and PresidentRai		CI	hief Financial Officer	David Patrick Delaney #
Vice President a	and SecretaryR	obert Mark Kessler	_		
		0'	THER		
Kevin James Casey, S	enior Investment Officer	Peter Keller, Ass	istant Controller#	Bryan James	Lane, Assistant Controller #
	artino, Vice President	William Stephen Mayne	es, Assistant Controller#	Cara Sue l	Mullen, Assistant Controller
	Principal Financial Officer htroller #			Tracy Louise Smit	h, Vice President and Treasurer#
		DIRECTORS	OR TRUSTEES		
David Patr	ick Delaney #	Randy J		Mary L	ouise Elizabeth Osborne
all of the herein described as statement, together with relat condition and affairs of the sa in accordance with the NAIC rules or regulations require di Furthermore, the scope of the	ssets were the absolute prop ted exhibits, schedules and ex- tid reporting entity as of the re Annual Statement Instruction fferences in reporting not rela- is attestation by the describe	erty of the said reporting ent cplanations therein contained porting period stated above, as and Accounting Practices ted to accounting practices a and officers also includes the i	ity, free and clear from any annexed or referred to, is a and of its income and deur and Procedures manual ex by procedures, according to elated corresponding elect	y liens or claims thereon, a full and true statement of ctions therefrom for the pe cept to the extent that: (1) the best of their informatic ronic filing with the NAIC,	t on the reporting period stated above, except as herein stated, and that this all the assets and liabilities and of the riod ended, and have been completed state law may differ; or, (2) that state ni, knowledge and belief, respectively when required, that is an exact copy gulators in lieu of or in addition to the
Randy Joo H	lwan Hyun	Robert	Mark Kessler		David Patrick Delaney
Chief Executive Office	, A -	Vice Presid	ent and Secretary		Chief Financial Officer

State of...... Arizona County of.... Maricopa

Subscribed and sworn to before me this

day of Janu

NOTARY PUBLIC (Seal)

LISA M LAMBERT Notary Public, State of Arizona Maricopa County Commission # 558484 My Commission Expires January 21, 2023

State of...... Arizona County of..... Maricopa

Subscribed and sworn to before me this

NOTARY PUBLIC (Seal)



State of...... Arizona County of.... Maricopa

Subscribed and sworn to before me this

rebruan Ja Mam NOTARY PUBLIC (Seal)



a. Is this an original filing? Yes [X] No []

b. If no,

State the amendment number
 Date filed

3. Number of pages attached......

ASSETS

		Current Year		Prior Year	
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)	99,430,497	0	99,430,497	104,736,623
2.	Stocks (Schedule D):				
	2.1 Preferred stocks	0	0	0	0
	2.2 Common stocks	0	0	0	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens	0	0	0	0
	3.2 Other than first liens	0	0	0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$	0	0	0	0
	4.2 Properties held for the production of income (less \$			0	0
	4.3 Properties held for sale (less \$			0	0
5.	Cash (\$484,063 , Schedule E - Part 1), cash equivalents (\$32,199,705 , Schedule E - Part 2) and short-term				
	investments (\$0 , Schedule DA)				
6.	Contract loans, (including \$				
7.	Derivatives (Schedule DB)				0
8.	Other invested assets (Schedule BA)				0
9.	Receivables for securities				
10.	Securities lending reinvested collateral assets (Schedule DL)				0
11.	Aggregate write-ins for invested assets				0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	132,210,640	0	132,210,640	124,606,161
13.	Title plants less \$0 charged off (for Title insurers	0			0
	only)				
14.	Investment income due and accrued	515,226	0	515,226	823,026
15.	Premiums and considerations: 15.1 Uncollected premiums and agents' balances in the course of collection.	6 000 754		6 000 754	5 000 000
		0,902,734	0		5,923,090
	15.2 Deferred premiums and agents' balances and installments booked but				
	deferred and not yet due (including \$0 earned but unbilled premiums)	0	0	٥	0
	15.3 Accrued retrospective premiums (\$	0		ļ0	0
	contracts subject to redetermination (\$	0	0	0	0
16.	Reinsurance:	0			
10.	16.1 Amounts recoverable from reinsurers	0	0	0	0
	16.2 Funds held by or deposited with reinsured companies			0	0
	16.3 Other amounts receivable under reinsurance contracts				0
17.	Amounts receivable relating to uninsured plans				0
					0
	Net deferred tax asset			516,869	1,344,357
19.	Guaranty funds receivable or on deposit		0	0	0
20.	Electronic data processing equipment and software			0	0
21.	Furniture and equipment, including health care delivery assets				
	(\$	0	0	0	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates			0	0
23.	Receivables from parent, subsidiaries and affiliates	4,670,997	0		0
24.	Health care (\$0) and other amounts receivable				316,510
25.	Aggregate write-ins for other than invested assets		0		0
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	148,920,047	1,983,038	146,937,009	133,013,144
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0	0
28.	Total (Lines 26 and 27)	148,920,047	1,983,038	146,937,009	133,013,144
	DETAILS OF WRITE-INS	_	_		_
1101.			0	0	0
1102.		0	0	0	0
1103.		0	0	0	0
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)		0	0	U
2501.	Current state income tax receivable		0	194,217	0
2502.			0	0	0
2503.			0	0	0
2598.	Summary of remaining write-ins for Line 25 from overflow page			104 217	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	194,217	0	194,217	0

LIABILITIES, CAPITAL AND SURPLUS

	LIABILITIES, CAP	IIAL AND	Current Year		Prior Year
	-	1	2	3	4
		Covered	Uncovered	Total	Total
1	Claims unpaid (less \$		8,069,771		46,300,751
	Accrued medical incentive pool and bonus amounts		0,003,777		
	Unpaid claims adjustment expenses		0		
	Aggregate health policy reserves, including the liability of	1,000,402		1,000,402	1,000,000
4. /	\$0 for medical loss ratio rebate per the Public				
	Health Service Act	11 929 875	0	11 929 875	11 437 653
5	Aggregate life policy reserves.				0
	Property/casualty unearned premium reserves.				0
	Aggregate health claim reserves.				0
8.	Premiums received in advance	0			0
	General expenses due or accrued.		0		6,931,720
	Current federal and foreign income tax payable and interest thereon	, 100,011			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	(including \$0 on realized capital gains (losses))	0	0	0	1,395,290
10.2	Net deferred tax liability				0
	Ceded reinsurance premiums payable				0
	Amounts withheld or retained for the account of others				0
	Remittances and items not allocated.				84,913
	Borrowed money (including \$0 current) and	·			
	interest thereon \$0 (including				
	\$0 current)	0	0	0	0
15.	Amounts due to parent, subsidiaries and affiliates			271,040	10,065,420
	Derivatives				0
	Payable for securities				0
	Payable for securities lending				0
	Funds held under reinsurance treaties (with \$0				
	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$0 certified reinsurers)	0	0	0	0
20. I	Reinsurance in unauthorized and certified (\$0)				
	companies	0	0	0	0
21.	Net adjustments in assets and liabilities due to foreign exchange rates		0	0	0
	Liability for amounts held under uninsured plans			_	0
	Aggregate write-ins for other liabilities (including \$0				
	current)	900,805	0	900,805	489,079
24.	Total liabilities (Lines 1 to 23)	74,112,123	8,069,771	82,181,894	80,123,801
	Aggregate write-ins for special surplus funds				0
26.	Common capital stock	xxx	XXX	0	0
	Preferred capital stock				0
28.	Gross paid in and contributed surplus.	xxx	XXX	21,000,000	21,000,000
	Surplus notes.				0
30.	Aggregate write-ins for other than special surplus funds	xxx	XXX	0	0
31.	Unassigned funds (surplus)	xxx	XXX	38,483,715	31,889,343
	Less treasury stock, at cost:				
;	32.10 shares common (value included in Line 26				
	\$	xxx	XXX	0	0
;	32.20 shares preferred (value included in Line 27				
	\$0)	xxx	xxx	0	0
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	xxx	XXX	64,755,115	52,889,343
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	146,937,009	133,013,144
	DETAILS OF WRITE-INS				
2301. l	Escheat Payable	900,805	0	900,805	489,079
2302.		0	0	0	0
2303.		0			0
2398.	Summary of remaining write-ins for Line 23 from overflow page				0
	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	900,805	0	900,805	489,079
2501. l	Estimated Health Insurer Fee	xxx	XXX	5,271,400	0
2502.		xxx	xxx	0	0
2503.					0
2598.	Summary of remaining write-ins for Line 25 from overflow page				0
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	5,271,400	0
3001.		XXX	xxx	0	0
3002.					0
3003.					0
	Summary of remaining write-ins for Line 30 from overflow page				0
	Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0

STATEMENT OF REVENUE AND EXPENSES

Number N			Current	Year	Prior Year
Memorar Materia,			1	2	3
Not permunit income (insulating \$ 0 one-health premunit income)					
9. Clargin in unwarred premium reserves and reserves for rate usefuls XOX 0 0 0 4. Fee for servincy (not of § 1 .0 medical experience) XOX 0 0 0 6. Aggregate wise run for clintor breath core related meetures XOX .0 0 0 0 6. Total recruiser (Lines 2 to 7) XOX .493 x87 x84 .034 x85 x87 x84 .0	1.	Member Months.	XXX	767,050	668,755
9. Clargin in unwarred premium reserves and reserves for rate usefuls XOX 0 0 0 4. Fee for servincy (not of § 1 .0 medical experience) XOX 0 0 0 6. Aggregate wise run for clintor breath core related meetures XOX .0 0 0 0 6. Total recruiser (Lines 2 to 7) XOX .493 x87 x84 .034 x85 x87 x84 .0					
1. Producestricky (cet of 5	2.				
6. Risk increases XXX	3.	Change in unearned premium reserves and reserve for rate credits	XXX	(492,222)	28,807,563
Aggregate writering for other health care revised reverues	4.	Fee-for-service (net of \$	XXX	0	0
7. Agringation with infinite from the nicht heremunes 20	5.	Risk revenue	xxx	0	0
7. Agringation with infinite from the nicht heremunes 20	6.	Aggregate write-ins for other health care related revenues	xxx	0	0
18. Total inventors (Linea 2 to 7)	7.				
Hospital and Medical:					
9. Hospitalhendrick benefits 31,30,985 20,885,50 21,820,981	0.				
10. Other professional services	9.	·	31 310 985	300 488 530	231 652 087
11 Outside referrals					
12 Emergency toom and out of areas					
13. Prescription drugs					
14. Aggregate write-ins for other hospital and medical 9 9,8 535 2,728, 891 15. Incentive pool, withhold adjustments and bonus amounts 9,7 41,510 397, 688, 355 2,728, 891 16. Subboild, Live 9 to 15) 97,674, 826 17. Not reinsurance recoveries 9,7 41,510 397, 688, 291 307, 674, 826 18. Total hospital and medical (Lines 10 minus 17) 57,141,510 397, 688, 291 307, 674, 385 19. Non-heath claims (net) 0 0 0 0 0 19. Company of the claims (net) 0 0 0 0 0 19. Company of the claims (net) 0 0 0 0 0 19. Company of the claims (net) 0 0 0 0 0 19. Company of the claims (net) 0 0 0 0 0 19. Company of the claims (net) 0 0 0 0 0 19. Company of the claims (net) 0 0 0 0 0 19. Company of the claims (net) 0 0 0 0 0 0 19. Company of the claims (net) 0 0 0 0 0 0 20. Total underwriting deductions (Lines 10 through 22) 57,141,510 449,519,733 385,424,439 21. Not underwriting gain or (lose) (Lines 8 minus 23) 0 0 0 0 0 0 0 0 0	12.				
16 Incentive pool, withhold adjustments and bonus amounts	13.				
15. Subtotal (Lines 9 to 15) 397,698,291 307,694,826 Less: 1. Net riensurance recoveries	14.	Aggregate write-ins for other hospital and medical	0	0	0
Less: 17. Not trinibution cerecoveries	15.	Incentive pool, withhold adjustments and bonus amounts	0	936,835	2,752,891
17. Net reinsurance racoveries	16.	Subtotal (Lines 9 to 15)	57,141,510	397,098,291	307,674,826
18. Total hospital and medical (Lines 16 minus 17) 397, 687, 219 307, 647, 345		Less:			
19. Non-health claims (net)	17.	Net reinsurance recoveries	0	10,072	27,481
Claims adjustment expenses, including \$ 17,667,912 cost containment expenses 0 23,793,380 17,158,685	18.	Total hospital and medical (Lines 16 minus 17)	57,141,510	397,088,219	307,647,345
Claims adjustment expenses, including \$ 17,667,912 cost containment expenses 0 23,793,380 17,158,685	19.	Non-health claims (net)	0	0	0
21. General administrative expenses	20				
22. Increase in reserves for life and accident and health contracts (including \$ 0 0 0 0 0 0 0 0 0					
increase in reserves for life only)				20,000,104	
23. Total underwriting deductions (Lines 18 through 22)	22.	, ,		•	
24. Net underwriting gain or (loss) (Lines 8 minus 23)					
25. Net investment income earned (Exhibit of Net Investment Income, Line 17)	23.				
26. Net realized capital gains (losses) less capital gains tax of \$ (14,208)	24.	Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	9,827,571	19,036,868
27. Net investment gains (losses) (Lines 25 plus 26)	25.				
28. Net gain or (loss) from agents' or premium balances charged off [(amount recovered \$ \$ 0) (amount charged off \$ 0)]	26.	Net realized capital gains (losses) less capital gains tax of \$(14,208)	0	6,529	(552,870)
\$ 0 (amount charged off \$ 3.367,128 300 Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 pix 28 plus 29) XXX 12,903,481 22,011,343 31. Federal and foreign income taxes incurred XXX 681,845 4,747,524 32. Net income (loss) (Lines 30 minus 31) XXX 12,221,636 17,263,819 DETAILS OF WRITE-INS 0601. XXX 0 0 0 0602. XXX 0 0 0 0603. XXX 0 0 0 0604. XXX 0 0 0 0609. Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above) XXX 0 0 0 0701. XXX 0 XXX 0 0 0 0 0702. XXX XXX 0 0 0	27.	Net investment gains (losses) (Lines 25 plus 26)	0	3,017,787	2,607,347
\$ 0 (amount charged off \$ 3.367,128 300 Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 pix 28 plus 29) XXX 12,903,481 22,011,343 31. Federal and foreign income taxes incurred XXX 681,845 4,747,524 32. Net income (loss) (Lines 30 minus 31) XXX 12,221,636 17,263,819 DETAILS OF WRITE-INS 0601. XXX 0 0 0 0602. XXX 0 0 0 0603. XXX 0 0 0 0604. XXX 0 0 0 0609. Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above) XXX 0 0 0 0701. XXX 0 XXX 0 0 0 0 0702. XXX XXX 0 0 0	28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered			
29. Aggregate write-ins for other income or expenses 0 58,123 367,128 30. Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29) XXX 12,903,481 22,011,343 31. Federal and foreign income taxes incurred XXX 681,845 4,747,524 32. Net income (loss) (Lines 30 minus 31) XXX 12,221,636 17,263,819 DETAILS OF WRITE-INS 0601. XXX 0 0 0602. XXX 0 0 0608. Summary of remaining write-ins for Line 6 from overflow page XXX 0 0 0701. XXX 0 0 0 0702. XXX 0 0 0 0703. XXX 0 0 0 0704. XXX 0 0 0 0705. XXX 0 0 0 0707. XXX 0 0 0 0707. XXX 0 0 0 0708. Summary of remaining write-ins for Line 7 from overflow page XXX 0 0			0	0	0
Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29).	29				367 128
27 plus 28 plus 29					
32. Net income (loss) (Lines 30 minus 31)	30.	27 plus 28 plus 29)	xxx	12,903,481	22,011,343
DETAILS OF WRITE-INS 0601. XXX 0	31.	Federal and foreign income taxes incurred	XXX	681,845	4,747,524
DETAILS OF WRITE-INS 0601. XXX 0	32.	Net income (loss) (Lines 30 minus 31)	xxx	12,221,636	17,263,819
0601. XXX 0 0 0602. XXX 0 0 0603. XXX 0 0 0698. Summary of remaining write-ins for Line 6 from overflow page XXX 0 0 0699. Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above) XXX 0 0 0701. XXX 0 0 0 0702. XXX 0 0 0 0703. XXX 0 0 0 0799. Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above) XXX 0 0 1401. XXX 0 0 0 1402. XXX 0 0 0 1403. XXX 0 0 0 1404. XXX 0 0 0 1409. XXX 0 0 0 1401. XXX 0 0 0 1402. XXX 0 0 0 <					, ,
0602. XXX 0 0 0603 XXX 0 0 0698. Summary of remaining write-ins for Line 6 from overflow page XXX 0 0 0699. Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above) XXX 0 0 0701. XXX 0 0 0 0702. XXX 0 0 0 0703. XXX 0 0 0 0798. Summary of remaining write-ins for Line 7 from overflow page XXX 0 0 0799. Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above) XXX 0 0 0 1401. 0 0 0 0 0 0 1402. 0 0 0 0 0 0 1403. 0 0 0 0 0 0 0 1498. Summary of remaining write-ins for Line 14 from overflow page 0 0 0 0 0 0 0 0	0601		YYY	0	0
0603 XXX 0 0 0698. Summary of remaining write-ins for Line 6 from overflow page XXX 0 0 0699. Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above) XXX 0 0 0701. XXX 0 0 0702. XXX 0 0 0703 XXX 0 0 0798. Summary of remaining write-ins for Line 7 from overflow page XXX 0 0 0799. Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above) XXX 0 0 1401. 0 0 0 0 1402. 0 0 0 0 1403. 0 0 0 0 1498. Summary of remaining write-ins for Line 14 from overflow page 0 0 0 1499. Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above) 0 0 0 2901. Regulatory Fines 0 0 0 0 2903. 0 0 0 0 2903. 0 0 0 <td></td> <td></td> <td></td> <td></td> <td></td>					
0698. Summary of remaining write-ins for Line 6 from overflow page XXX 0 0 0699. Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above) XXX 0 0 0701. XXX 0 0 0702. XXX 0 0 0703. XXX 0 0 0798. Summary of remaining write-ins for Line 7 from overflow page XXX 0 0 0799. Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above) XXX 0 0 1401. 0 0 0 0 1402. 0 0 0 0 1403. 0 0 0 0 1498. Summary of remaining write-ins for Line 14 from overflow page 0 0 0 1499. Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above) 0 0 0 2901. Regulatory Fines 0 58,123 367,128 2902. 0 0 0 0 2903. 0 0 0 0 2909. Summary of remaining write-ins for Line 29 from					
0699. Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above) XXX 0 0 0701. XXX 0 0 0 0702. XXX 0 0 0 0703. XXX 0 0 0 0799. Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above) XXX 0 0 0 1401. 0 0 0 0 0 0 1402. 0 0 0 0 0 0 0 1403. 0					
0701. XXX 0 0 0 0702. XXX 0 0 0 0703 XXX 0 0 0 0798. Summary of remaining write-ins for Line 7 from overflow page XXX 0 0 0799. Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above) XXX 0 0 0 1401. 0 0 0 0 0 0 1402. 0 0 0 0 0 0 1403. 0 0 0 0 0 0 1498. Summary of remaining write-ins for Line 14 from overflow page 0 0 0 0 2901. Regulatory Fines 0 0 58,123 367,128 2902. 0 0 0 0 0 2903 0 0 0 0 2998. Summary of remaining write-ins for Line 29 from overflow page 0 0 0 0				0	
0702. XXX 0 0 0703 XXX 0 0 0798. Summary of remaining write-ins for Line 7 from overflow page XXX 0 0 0799. Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above) XXX 0 0 1401. 0 0 0 0 1402. 0 0 0 0 1403. 0 0 0 0 1498. Summary of remaining write-ins for Line 14 from overflow page 0 0 0 1499. Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above) 0 0 0 2901. Regulatory Fines 0 58,123 367,128 2902. 0 0 0 0 2903. 0 0 0 0 2998. Summary of remaining write-ins for Line 29 from overflow page 0 0 0 0		·		0	
0703 XXX 0 0 0 0798. Summary of remaining write-ins for Line 7 from overflow page XXX 0 0 0799. Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above) XXX 0 0 1401. 0 0 0 0 1402. 0 0 0 0 1403. 0 0 0 0 1498. Summary of remaining write-ins for Line 14 from overflow page 0 0 0 1499. Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above) 0 0 0 2901. Regulatory Fines 0 58,123 367,128 2902. 0 0 0 2903 0 0 0 2998. Summary of remaining write-ins for Line 29 from overflow page 0 0 0					0
0798. Summary of remaining write-ins for Line 7 from overflow page XXX 0					0
0799. Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above) XXX 0 0 1401. .					0
1401. 0 0 0 0 1402. 0 0 0 0 1403. 0 0 0 0 1498. Summary of remaining write-ins for Line 14 from overflow page 0 0 0 0 1499. Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above) 0 0 0 0 2901. Regulatory Fines 0 58,123 367,128 2902. 0 0 0 0 2903. 0 0 0 0 2998. Summary of remaining write-ins for Line 29 from overflow page 0 0 0					
1402.				0	-
1403.					
1498. Summary of remaining write-ins for Line 14 from overflow page 0 0 0 1499. Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above) 0 0 0 2901. Regulatory Fines 0 58,123 367,128 2902. 0 0 0 0 2903. 0 0 0 0 2998. Summary of remaining write-ins for Line 29 from overflow page 0 0 0 0					
1499. Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above) 0 0 0 2901. Regulatory Fines 0 58,123 367,128 2902. 0 0 0 0 2903. 0 0 0 0 2998. Summary of remaining write-ins for Line 29 from overflow page 0 0 0					_
2901. Regulatory Fines 0 58,123 367,128 2902. 0 0 0 2903. 0 0 0 2998. Summary of remaining write-ins for Line 29 from overflow page 0 0 0					
2902.					
2903		Regulatory Fines		, .	367 , 128
2998. Summary of remaining write-ins for Line 29 from overflow page	2902.			0	0
	2903				0
2999. Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above) 0 58,123 367,128	2998.	Summary of remaining write-ins for Line 29 from overflow page			
	2999.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	58,123	367,128

STATEMENT OF REVENUE AND EXPENSES (Continued)

		1 Current Year	2 Prior Year
		Current real	FIIOI (Edi
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year.	52,889,343	36,287,613
34.	Net income or (loss) from Line 32	12,221,636	17,263,819
35.	Change in valuation basis of aggregate policy and claim reserves	0	0
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$	0	0
37.	Change in net unrealized foreign exchange capital gain or (loss)	0	0
38.	Change in net deferred income tax	(842,653)	402,742
39.	Change in nonadmitted assets	486,789	(1,064,831)
40	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles.	0	0
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus.	0	0
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)	0	0
	45.3 Transferred from capital	0	0
46.	Dividends to stockholders	0	0
47.	Aggregate write-ins for gains or (losses) in surplus	0	0
48.	Net change in capital and surplus (Lines 34 to 47)	11,865,772	16,601,730
49.	Capital and surplus end of reporting period (Line 33 plus 48)	64,755,115	52,889,343
	DETAILS OF WRITE-INS		
4701.		0	0
4702.		0	0
4703.		0	0
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

CASH FLOW

		1	2
		Current Year	Prior Year
	Cash from Operations		
1.	Premiums collected net of reinsurance	458,859,882	343,525,085
2.	Net investment income	3,058,049	2,884,004
3.	Miscellaneous income	0	0
4.	Total (Lines 1 through 3)	461,917,931	346,409,089
5.	Benefit and loss related payments	386,091,454	297,893,228
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0
7.	Commissions, expenses paid and aggregate write-ins for deductions	50,451,928	43,379,831
8.	Dividends paid to policyholders	0	0
9.	Federal and foreign income taxes paid (recovered) net of \$	3,989,233	3,083,727
10.	Total (Lines 5 through 9)	440,532,615	344,356,786
11.	Net cash from operations (Line 4 minus Line 10)	21,385,316	2,052,303
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds	41,233,455	75,047,724
	12.2 Stocks	0	0
	12.3 Mortgage loans	0	0
	12.4 Real estate	0	0
	12.5 Other invested assets	0	0
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments	33	(14)
	12.7 Miscellaneous proceeds	0	0
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	41,233,488	75,047,710
13.	Cost of investments acquired (long-term only):		
	13.1 Bonds	46,240,236	76,204,786
	13.2 Stocks	0	0
	13.3 Mortgage loans	0	0
	13.4 Real estate	0	0
	13.5 Other invested assets	0	0
	13.6 Miscellaneous applications	28,437	67,938
	13.7 Total investments acquired (Lines 13.1 to 13.6)	46,268,673	76,272,724
14.	Net increase (decrease) in contract loans and premium notes	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(5,035,185)	(1,225,014)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		^
	16.1 Surplus notes, capital notes		0
	16.2 Capital and paid in surplus, less treasury stock		
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		0
	16.5 Dividends to stockholders		0
	16.6 Other cash provided (applied)		(5,717,946)
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	(3,467,963)	(5,717,946)
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	12,882,168	(4,890,657)
19.	Cash, cash equivalents and short-term investments:		
-	19.1 Beginning of year	19,801,600	24,692,257
	19.2 End of year (Line 18 plus Line 19.1)	32,683,768	19,801,600

Note: Supplemental disclosures of cash flow information for non-cash transactions:		
20.0001. Non-cash investment exchanges	13,751,486	3,488,539
		·

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

		, vi	IAL I 313 C		TIONS D						1
		1	2 Comprehensive	3 Medicare	4 Dental	5 Vision	6 Federal Employees Health	7 Title XVIII	8 Title XIX	9	10 Other
		Total	(Hospital & Medical)	Supplement	Only	Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
1.	Net premium income	459,839,546	0	0	0	0	0	0	459,839,546	0	0
	Change in unearned premium reserves and reserve for rate credit	(492,222)	0	0	0	0	0	0	(492,222)	0	0
3.	Fee-for-service (net of \$0	,							, , ,		
	medical expenses)	0	0	0	0	0	0	0	0	0	XXX
4.	Risk revenue	0	0	0	0	0	0	0	0	0	XXX
5.	Aggregate write-ins for other health care related revenues	0	0	0	0	0	0	0	0	0	XXX
6.	Aggregate write-ins for other non-health care related revenues	0	xxx	xxx	XXX	XXX	xxx	xxx	xxx	xxx	0
7.	Total revenues (Lines 1 to 6)	459,347,324	0	0	0	0	0	0	459,347,324	0	0
8.	Hospital/medical benefits	300,488,530	0	0	0	0	0	0		0	XXX
9.	Other professional services	12,735,761	0	0	0	0	0	0	12,735,761	0	XXX
10.	Outside referrals	15,705,425	0	0	0	0	0	0	15,705,425	0	XXX
11.	Emergency room and out-of-area	24,705,040	0	0	0	0	0	0	24,705,040	0	XXX
12.	Prescription drugs	42,526,700	0	0	0	0	0	0	42,526,700	0	XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0	0	0	0	0	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts	936,835	0	0	0	0	0	0	936,835	0	XXX
15.	Subtotal (Lines 8 to 14)	397,098,291	0	0	0	0	0	0	397,098,291	0	XXX
16.	Net reinsurance recoveries	10,072	0	0	0	0	0	0	10,072	0	XXX
17.	Total medical and hospital (Lines 15 minus 16)	397,088,219	0	0	0	0	0	0	397,088,219	0	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
19.	Claims adjustment expenses including										
	\$17,667,912 cost containment expenses	23,793,380	0	0	0	0	0	0	23,793,380	0	0
20.	General administrative expenses	28,638,154	0	0	0	0	0	0	28,638,154	0	0
21.	Increase in reserves for accident and health contracts	0	0	0	0	0	0	0	0	0	XXX
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
23.	Total underwriting deductions (Lines 17 to 22)	449,519,753	0	0	0	0	0	0	449,519,753	0	0
24.	Total underwriting gain or (loss) (Line 7 minus Line 23)	9,827,571	0	0	0	0	0	0	9,827,571	0	0
0501.	DETAILS OF WRITE-INS										XXX
0502.								•			XXX
0502.								• • • • • • • • • • • • • • • • • • • •			XXX
	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	XXX
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	XXX
0601.	Totals (Elifes 6501 tilla 6505 plas 6550) (Elife 5 above)	Ů	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	7000
0601.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0698.	Summary of remaining write-ins for Line 6 from overflow page	n	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	n
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.							ļ				XXX
1302.							ļ				XXX
1303.							ļ				XXX
1398.	Summary of remaining write-ins for Line 13 from overflow page	0	0	0	0	0	0	0	0	0	xxx
1399.	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	0	0	0	0	0	0	0	0	0	XXX

7

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

FACT 1 - FICEWIOWS	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical)	0	0	0	0
2. Medicare Supplement	0	0	0	0
3. Dental only	0	0	0	0
4. Vision only	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0
6. Title XVIII - Medicare	0	0	0	0
7. Title XIX - Medicaid	460,394,513	0	554,967	459,839,546
8. Other health	0	0	0	0
9. Health subtotal (Lines 1 through 8)	460,394,513	0	554,967	459,839,546
10. Life	0	0	0	0
11. Property/casualty	0	0	0	0
12. Totals (Lines 9 to 11)	460,394,513	0	554,967	459,839,546

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

		4 1	•		IMS INCURRED DU	KING THE TEAK		ı –			40
		1	2	3	4	5	6 Federal	7	8	9	10
							Employees	Title	Title		
			Comprehensive	Medicare			Health	XVIII	XIX		Other
		Total	(Hospital & Medical)	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
1.	Payments during the year:		,		•	•					
	1.1 Direct	384,497,988	0	0	0	0	0	0	384,497,988	0	
	1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	
	1.3 Reinsurance ceded	37,553	0	0	0	0	0	0		0	
	1.4 Net	384,460,435	0	0	0	0	0	0	384,460,435	0	
	Paid medical incentive pools and bonuses	1,631,019	0	0	0	0	0	0	1,631,019	0	
	Claim liability December 31, current year from Part 2A:	, ,		_					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
	3.1 Direct	57,203,566	0	0	0	0	0	0	57,203,566	0	
	3.2 Reinsurance assumed	n	0	0	0	0	0	0	0 ,200,000	0	
	3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	
	3.4 Net	57,203,566	o	 0		٥	Λ	n	57,203,566		
	Claim reserve December 31, current year from Part 2D:			0	0						
4.		٥	0	٥	0	٥	0	_	٥	0	
	4.1 Direct						0		0		
				0	0	0	0	0	0		
	4.3 Reinsurance ceded		0	0	0	0	0	0	0		
	4.4 Net	0	0	0	0	0	0	0	0	0	
5.	Accrued medical incentive pools and bonuses, current	070 000	0	0	0	0			070 000	0	
_	year	873,932		0	0	0	0	0	873,932		
	Net healthcare receivables (a)	(788, 134)	0	0	0	0	0	0	(788,134)	0	
7.	Amounts recoverable from reinsurers December 31,	٥	0	0	0	0			0	0	
	current year		<u>.</u> U	0	0	0	0	0	0	0	
	Claim liability December 31, prior year from Part 2A:										
	8.1 Direct	46,328,232	0	0	0	0	0	0	46,328,232	0	
	8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	
	8.3 Reinsurance ceded	27,481	0	0	0	0	0	0	27,481	0	
	8.4 Net	46,300,751	0	0	0	0	0	0	46,300,751	0	
	Claim reserve December 31, prior year from Part 2D:										
	9.1 Direct	0	0	0	0	0	0	0	0	0	
	9.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	
	9.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	
	9.4 Net	0	0	0	0	0	0	0	0	0	
10.	Accrued medical incentive pools and bonuses, prior year	1,568,116	0	0	0	0	0	0	1,568,116	0	
11.	Amounts recoverable from reinsurers December 31,	, ,							, ,		
	prior year	0	0	0	0	0	0	0	0	0	
12.	Incurred Benefits:										
	12.1 Direct	396, 161, 456	0	0	0	0	0	0	396, 161, 456	0	
	12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	
	12.3 Reinsurance ceded	10,072	0	0	0	0	0	0	10.072	0	
	12.4 Net	396, 151, 384	0	0	0	0	0	0	,	0	
12	Incurred medical incentive pools and bonuses	936,835	0	0	0	0	0	0	936,835	n	

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1	, ,		NIS LIABILITY END			,		,	
	1	2 Comprehensive	3 Medicare	4	5	6 Federal Employees Health	7 Title XVIII	8 Title XIX	9	10 Other
	Total	(Hospital & Medical)	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
Reported in Process of Adjustment:										
1.1 Direct	14,891,716	0	0	0	0	0	0	14,891,716	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
1.4 Net	14,891,716	0	0	0	0	0	0	14,891,716	0	0
Incurred but Unreported:										
2.1 Direct	42,311,850		0	0	0	0	0	42,311,850	0	0
2.2 Reinsurance assumed	0		0	0	0	0	0	0	0	0
2.3 Reinsurance ceded	0		0	0	0	0	0	0	0	0
2.4 Net	42,311,850	0	0	0	0	0	0	42,311,850	0	0
Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	0	0	0	0	0	0	0	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
3.4 Net	0	0	0	0	0	0	0	0	0	0
4. TOTALS:										
4.1 Direct	57,203,566	0	0	0	0	0	0	57,203,566	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	57,203,566	0	0	0	0	0	0	57,203,566	0	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE									
	Claima Daid F	During the Year	Claim Reserve a	ind Claim Liability of Current Year	5	6			
	1	2	3	4		Estimated Claim			
	·	_	· ·			Reserve and Claim			
	On Claims Incurred		On Claims Unpaid		Claims Incurred	Liability			
Line of Business	Prior to January 1 of Current Year	On Claims Incurred During the Year	December 31 of Prior Year	On Claims Incurred During the Year	In Prior Years (Columns 1 + 3)	December 31 of Prior Year			
Lille Of Dustriess	Of Current Year	During the real	FIIOI Teal	During the real	(Colullins 1 + 3)	FIIOI Teal			
Comprehensive (hospital and medical)	0	0	0	0	0	0			
Medicare Supplement	0	0	0	0	0	0			
					•				
3. Dental Only	0	0	0	0	0	0			
4. Vision Only	0	0	0	0	0	0			
5. Federal Employees Health Benefits Plan	0	0	0	0	0	0			
6. Title XVIII - Medicare	0	0	0	0	0	0			
7 Title XIX - Medicaid	38,941,782	345,518,653	4,585,390	52,618,176	43,527,172	46,300,751			
8. Other health	0	0	0	0	0	0			
9. Health subtotal (Lines 1 to 8)	38,941,782	345,518,653	4,585,390	52,618,176	43,527,172	46,300,751			
10. Healthcare receivables (a)	0	1,942,744	0	0	0	2,730,878			
11. Other non-health	0	0	0	0	0	0			
12. Medical incentive pools and bonus amounts	750,007	881,012	0	873,932	750,007	1,568,116			
13. Totals (Lines 9 - 10 + 11 + 12)	39,691,789	344,456,921	4,585,390	53,492,108	44,277,179	45,137,989			

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

Goddon A - 1 aid floatin Grainis - Goniprenensive (flospital & f	Cumulative Net Amounts Paid							
	1	2	3	4	5			
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019			
1. Prior								
2. 2015								
3. 2016	XXX							
4. 2017	XXX	XXX						
5. 2018	XXX	XXX	XXX					
6. 2019	XXX	XXX	XXX	XXX				

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

Toolion 2 mounta nount of the promoter (nooph	ai a incaicai,				
	Sum of Cumulative N	ve Pool and Bonuses			
	1	2	3	4	5
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019
1. Prior					
2. 2015					
3. 2016	XXX				
4. 2017	XXX	XXX			
5. 2018	XXX	XXX	XXX		
6. 2019	XXX	XXX	XXX	XXX	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	. 2015										
	2016										
						· · · · · · · · · · · · · · · · · · ·					
3	. 2017					<u>-</u>					
4	. 2018										
5	i. 2019										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Medicare Supplement

Coolon A Tala noath Claime moaleare cappionism	Cumulative Net Amounts Paid				
	1	2	3	4	5
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019
1. Prior					
2. 2015	,				
3. 2016	XXX				
4. 2017	XXX	XXX			
5. 2018	XXX	XXX	XXX		
6. 2019	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Medicare Supplement

occion B incarred ricardi elamic incarcare cappion								
	Sum of Cumulative N	ve Pool and Bonuses						
	1 2 3							
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019			
1. Prior								
2. 2015								
3. 2016	XXX							
4. 2017	XXX	XXX						
5. 2018	XXX	XXX	XXX					
6. 2019	XXX	XXX	XXX	XXX				

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Medicare Supplement

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	. 2015										
	. 2016										
3	. 2017										
4	. 2018										
5	. 2019									!	

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Dental Only

Cumulative Net Amounts Paid					
	1	2	3	4	5
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019
1. Prior					
2. 2015	,				
3. 2016	XXX				
4. 2017	XXX	XXX			
5. 2018	XXX	XXX	XXX		
6. 2019	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Dental Only

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool a Outstanding at End of Year						
Year in Which Losses Were Incurred	1 2015	2 2016	3 2017	4 2018	5 2019		
1. Prior							
2. 2015							
3. 2016 4. 2017	XXX	XXX					
5. 2018	XXX	XXX	XXX				
6. 2019	XXX	XXX	XXX	XXX			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Dental Only

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	2015										
2	2016										
۷.											
3.	2017				<i></i>						
4.	2018										
5.	2019				_						

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Vision Only

	Cumulative Net Amounts Paid				
	1	2	3	4	5
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019
1. Prior					
2. 2015	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
3. 2016	XXX				
4. 2017	XXX	XXX			
5. 2018	XXX	XXX	XXX		
6. 2019	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Vision Only

		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive F Outstanding at End of Year						
		1	2	3	4	5		
	Year in Which Losses Were Incurred	2015	2016	2017	2018	2019		
1.	Prior							
2.	2015							
3.	2016	XXX						
4.	2017	XXX	XXX					
5.	2018	XXX	XXX	XXX				
6	2019	xxx	XXX	XXX	XXX			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Vision Only

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	2015										
2.	2016										
3	2017							*			
4.	2018										
5.	2019										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Federal Employees Health Benefits Plan Premium

Section A - 1 and fleating Stating - 1 ederal Employees fleating Benefits	Cumulative Net Amounts Paid						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019		
1. Prior							
2. 2015							
3. 2016	XXX						
4. 2017	XXX	XXX					
5. 2018	XXX	XXX	XXX				
6. 2019	XXX	XXX	XXX	XXX			

Section B - Incurred Health Claims - Federal Employees Health Benefits Plan Premium

Coulon B mounted nearth ording it caeral Employees nearth								
	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Outstanding at End of Year							
	1	2	3	4	5			
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019			
1. Prior								
2. 2015								
3. 2016	XXX							
4. 2017	XXX	XXX						
5. 2018	XXX	XXX	XXX					
6. 2019	XXX	XXX	XXX	XXX				

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Federal Employees Health Benefits Plan Premium

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2015										
2.	2016										
3.	2017										
4.	2018										
5.	2019				_	T -					

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

Cumulative Net Amounts Paid					
	1	2	3	4	5
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019
1. Prior					
2. 2015					
3. 2016	XXX				
4. 2017	XXX	XXX			
5. 2018	XXX	XXX	XXX		
6. 2019	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and B Outstanding at End of Year							
	1	2	3	4	5			
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019			
1. Prior								
2. 2015								
3. 2016	XXX							
4. 2017	XXX	XXX						
5. 2018	XXX	XXX	XXX					
6. 2019	XXX	XXX	XXX	XXX				

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	2015										
2.	2016										
3	2017							*			
4.	2018										
5.	2019										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XIX

		Cumulative Net Amounts Paid							
		1	2	3	4	5			
	Year in Which Losses Were Incurred	2015	2016	2017	2018	2019			
1.	Prior	0	0	0	0	0			
2.	2015	29,914	38,950	39,779	39,779	39,779			
3.	2016	XXX	84,914	106,850	106,850	106,850			
4.	2017	XXX	XXX	153,232	182,128	182,128			
5.	2018	XXX	XXX	XXX	266,266	305,958			
6.	2019	XXX	XXX	XXX	XXX	344,457			

Section B - Incurred Health Claims - Title XIX

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuse Outstanding at End of Year							
	1 2 3 4							
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019			
1. Prior	0	0	(5)	(5)	(5)			
2. 2015	64,453	41,149	39,817	39,817	39,817			
3. 2016	XXX	117,362	107,959	107,959	107,959			
4. 2017	XXX	XXX	189,067	218,531	218,531			
5. 2018	XXX	XXX	XXX	313,567	357,844			
6. 2019	XXX	XXX	XXX	XXX	397,949			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims	S		Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2015	68,390	39,779	4,136	10.4	43,915	64.2	0	0	43,915	64.2
2. 2016	137,983	106,850	7,984	7.5	114,834	83.2	0	0	114,834	83.2
3. 2017	233,756	182,128	10,270	5.6	192,398	82.3	0	0	192,398	82.3
4. 2018		305,958	17, 159	5.6	323,117	88.7	4,585	0	327,702	90.0
5. 2019	459,347	344,457	23,946	7.0	368,403	80.2	53,492	1,698	423,593	92.2

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

(\$000 Omitted) Section A - Paid Health Claims - Other

	Cumulative Net Amounts Paid							
	1	2	3	4	5			
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019			
1. Prior								
2. 2015								
3. 2016	XXX							
4. 2017	XXX	XXX						
5. 2018	XXX	XXX	XXX					
6. 2019	XXX	XXX	XXX	XXX				

Section B - Incurred Health Claims - Other

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonu. Outstanding at End of Year							
Year in Which Losses Were Incurred	1 2015	2 2016	3 2017	4 2018	5 2019			
1. Prior								
2. 2015								
3. 2016	XXX							
4. 2017	XXX	XXX						
5. 2018	XXX	XXX	XXX					
6. 2019	XXX	XXX	XXX	XXX				

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	. 2015										
	2016										
						· · · · · · · · · · · · · · · · · · ·					
3	. 2017					<u>-</u>					
4	. 2018										
5	i. 2019										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

	Cumulative Net Amounts Paid						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019		
1. Prior	0	0	0	0	0		
2. 2015	29,914	38,950	39,779	39,779	39,779		
3. 2016	XXX	84,914	106,850	106,850	106,850		
4. 2017	XXX	XXX	153,232	182, 128	182, 128		
5. 2018	XXX	XXX	XXX	266,266	305,958		
6. 2019	XXX	XXX	XXX	XXX	344,457		

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonus Outstanding at End of Year					
	1 2 3 4					
Year in Which Losses Were Incurred	2015	2016	2017	2018	2019	
1. Prior	0	0	(5)	(5)	(5)	
2. 2015	64,453	41,149	39,817	39,817	39,817	
3. 2016	XXX	117,362	107,959	107,959	107,959	
4. 2017	XXX	XXX	189,067	218,531	218,531	
5. 2018	XXX	XXX	XXX	313,567	357,844	
6. 2019	XXX	XXX	XXX	XXX	397,949	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims	S		Claim Adjustment	Claim Adjustment (Col. 3/2) F		nents (Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2015	68,390	39,779	4,136	10.4	43,915	64.2	0	0	43,915	64.2
2. 2016	137,983	106,850	7,984	7.5	114,834	83.2	0	0	114,834	83.2
3. 2017	233,756	182,128	10,270	5.6	192,398	82.3	0	0	192,398	82.3
4. 2018		305,958	17, 159	5.6	323,117	88.7	4,585	0	327,702	90.0
5. 2019	459,347	344,457	23,946	7.0	368,403	80.2	53,492	1,698	423,593	92.2

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY										
		1 Total	2 Comprehensive (Hospital & Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other
				.,	,	,		Medicare	iviedicaid	Otner
	Unearned premium reserves	0	0	0	0	0	0	0	0	0
2.	Additional policy reserves (a)	0	0	0	0	0	0	0	0	0
3.	Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0
4.	Reserve for rate credits or experience rating refunds (including									
	\$0) for investment income	11,929,875	0	0	0	0	0	0	11,929,875	0
5.	Aggregate write-ins for other policy reserves	0	0	0	0	0	0	0	0	0
6.	Totals (gross)	11,929,875	0	0	0	0	0	0	11,929,875	0
7.	Reinsurance ceded	0	0	0	0	0	0	0	0	0
8.	Totals (Net)(Page 3, Line 4)	11,929,875	0	0	0	0	0	0	11,929,875	0
9.	Present value of amounts not yet due on claims		0	0	0	0	0	0	0	0
10.	Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0
11.	Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0
12.	Totals (gross)	0	0	0	0	0	0	0	0	0
13.	Reinsurance ceded	0	0	0	0	0	0	0	0	0
14.	Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	C
	DETAILS OF WRITE-INS									
0501.										
0502.										
0503.										
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0
1103.										
	Summary of remaining write-ins for Line 11 from overflow page		0	0	0	0	0	0	n	0
	Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	n	0		0	0	0			
	() () () () () () () () () ()	ı	ı	U	ı	1 0	1 0	1 0	1 0	

(a) Includes \$ ______0 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

			YSIS OF EXPENSE		4	E
		Claim Adjustme	2 Other Claim	3 General	4	5
		Containment Expenses	Adjustment Expenses	Administrative Expenses	Investment Expenses	Total
1.	Rent (\$0 for occupancy of					
	own building)	0	111,153	629,825	3,787	744,765
2.	Salary, wages and other benefits			7, 111,311		23,000,279
3.	Commissions (less \$0	, , .	, , , ,	, ,	,, ,	,
0.	ceded plus \$0 assumed)	0	0	0	0	0
4.	Legal fees and expenses					168,349
5.	Certifications and accreditation fees			0		0
	Auditing, actuarial and other consulting services					
6.	Traveling expenses					652,133
7.	- ·					ŕ
8.	Marketing and advertising					
9.	Postage, express and telephone					920,698
10.	Printing and office supplies					
11.	Occupancy, depreciation and amortization					0
12.	Equipment	0	77,749	440,550	2,580	520,879
13.	Cost or depreciation of EDP equipment and software	0	181,981	1,031,164	1,542	1,214,687
14.	Outsourced services including EDP, claims, and other services	3,598,906	1,000,687	2,071,301	14,142	6,685,036
15.	Boards, bureaus and association fees	32,289	8,978	18,584	223	60,074
16.	Insurance, except on real estate			171,504		201,843
17.	Collection and bank service charges			2,603		11,416
18.	Group service and administration fees					0
	Reimbursements by uninsured plans			0		0
19.				0		
20.	Reimbursements from fiscal intermediaries			468,247		0
21.	Real estate expenses					
22.	Real estate taxes		0	88,663	0	88,663
23.	Taxes, licenses and fees:	_	_			
	23.1 State and local insurance taxes		0	` ' '	0	(333,733
	23.2 State premium taxes			0		0
	23.3 Regulatory authority licenses and fees					
	23.4 Payroll taxes	1,590,763	442,317	915,542	2,959	2,951,581
	23.5 Other (excluding federal income and real estate taxes)	0	0	0	0	0
24.	Investment expenses not included elsewhere	0	0	0	0	0
25.	Aggregate write-ins for expenses	0	0	(312,179)	0	(312,179
26.	Total expenses incurred (Lines 1 to 25)	17,667,912	6,125,468	28,638,154	159,751	(a)52,591,285
27.	Less expenses unpaid December 31, current year.	1,261,181	437,251	9, 199,847	0	10,898,279
28.	Add expenses unpaid December 31, prior year		404,850	6,931,720	0	8,782,579
29.	Amounts receivable relating to uninsured plans, prior year		0	0	0	0
30.	Amounts receivable relating to uninsured plans, current year		0	0	0	0
31.	Total expenses paid (Lines 26 minus 27 plus 28					
	minus 29 plus 30) DETAILS OF WRITE-INS	17,852,740	6,093,067	26,370,027	159,751	50,475,585
2501.		0	0	(159,751)	0	(159,751
2502.	Loss adjustment expense			(152,428)		(152,428
2502.	2003 adjustment expense			(102,420)		
2598.			0	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25	0	0	(312,179)		(312, 179
(a) India	above) des management fees of \$41,391,206	to affiliates and \$	-	n-affiliates.	0	(312,179

EXHIBIT OF NET INVESTMENT INCOME

			1	2
				Earned During Yea
1.	U.S. government bonds	(a)	1,357,653	1, 168, 37
1.1	Bonds exempt from U.S. tax	. (a)	0	
1.2	Other bonds (unaffiliated)	(a)	1,648,888	1,530,36
1.3	Bonds of affiliates	(a)	0	
2.1	Preferred stocks (unaffiliated)	(b)	0	
2.11	Preferred stocks of affiliates	(b)	0	
2.2	Common stocks (unaffiliated)		0	
2.21	Common stocks of affiliates		0	
3.	Mortgage loans		0	
4.	Real estate	(d)	0	
5	Contract Loans		0	
6	Cash, cash equivalents and short-term investments	(e)	469,333	469,34
7	Derivative instruments	(f)	0	
8.	Other invested assets		0	
9.	Aggregate write-ins for investment income		2,934	2,93
10.	Total gross investment income		3,478,808	3,171,00
11.	Investment expenses			(g)156,79
12.	Investment taxes, licenses and fees, excluding federal income taxes			(g)2,95
13.	Interest expense			(h)
14.	Depreciation on real estate and other invested assets			(i)
15.	Aggregate write-ins for deductions from investment income			
16.	Total deductions (Lines 11 through 15)			159,75
17.	Net investment income (Line 10 minus Line 16)			3,011,25
	DETAILS OF WRITE-INS			
0901.	Miscellaneous Interest Received		2,934	2,93
0902.			· · · · · · · · · · · · · · · · · · ·	<i>'</i>
0903.				
0998.	Summary of remaining write-ins for Line 9 from overflow page		0	
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)		2.934	
1501.			<i>'</i>	,
1502.				
1503.				
1598.	Summary of remaining write-ins for Line 15 from overflow page			
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)			

(a) Includes \$	328,758	accrual of discount less \$67,749	amortization of premium and less \$216,031	paid for accrued interest on purchases.
(b) Includes \$	0	accrual of discount less \$0	amortization of premium and less \$0	paid for accrued dividends on purchases
(c) Includes \$	0	accrual of discount less \$0	amortization of premium and less \$0	paid for accrued interest on purchases.
(d) Includes \$	0	for company's occupancy of its own building	s; and excludes \$0 interest on encu	mbrances.
(e) Includes \$	469,201	accrual of discount less \$0	amortization of premium and less \$0	paid for accrued interest on purchases.
(f) Includes \$	0	accrual of discount less \$0	amortization of premium.	
	and Separate Acco		.0 investment taxes, licenses and fees, excluding fede	eral income taxes, attributable to
(h) Includes \$	0	interest on surplus notes and \$	0 interest on capital notes.	
(i) Includes \$	٥	depreciation on real estate and \$	depreciation on other invested assets	

EXHIBIT OF CAPITAL GAINS (LOSSES)

	LAIIIDII			- (/	_
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	(2,554)		(2,554)	0	0
1.1	Bonds exempt from U.S. tax	0	0	0	0	0
1.2	Other bonds (unaffiliated)	(5, 157)	0	(5, 157)	0	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans	0	0	0	0	0
4.	Real estate	0	0	0	0	0
5.	Contract loans	0	0	0	0	0
6.	Cash, cash equivalents and short-term investments	32	0	32	0	0
7.	Derivative instruments	0	0	0	0	0
8.	Other invested assets	0	0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	(7,679)	0	(7,679)	0	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0	0	0	0

EXHIBIT OF NON-ADMITTED ASSETS

	EXHIBIT OF NON-ADMITTED ASSETS 1 2 3										
		Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)							
1.	Bonds (Schedule D)	0	0	0							
2.	Stocks (Schedule D):										
	2.1 Preferred stocks	0	0	0							
	2.2 Common stocks	0	0	0							
3.	Mortgage loans on real estate (Schedule B):										
	3.1 First liens	0	0	0							
	3.2 Other than first liens	0	0	0							
4.	Real estate (Schedule A):										
	4.1 Properties occupied by the company	0	0	0							
	4.2 Properties held for the production of income.	0	0	0							
	4.3 Properties held for sale		0								
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)		0	0							
6.	Contract loans	0	0	0							
7.	Derivatives (Schedule DB)	0	0	0							
8.	Other invested assets (Schedule BA)	0	0	0							
9.	Receivables for securities	0	0	0							
10.	Securities lending reinvested collateral assets (Schedule DL)	0	0	0							
11.	Aggregate write-ins for invested assets										
12.	Subtotals, cash and invested assets (Lines 1 to 11)										
13.	Title plants (for Title insurers only)										
14.	Investment income due and accrued										
15.	Premiums and considerations:										
	15.1 Uncollected premiums and agents' balances in the course of collection	0	0	0							
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due	_									
	15.3 Accrued retrospective premiums and contracts subject to redetermination		0	0							
16.	Reinsurance:										
	16.1 Amounts recoverable from reinsurers	0	0	0							
	16.2 Funds held by or deposited with reinsured companies			0							
	16.3 Other amounts receivable under reinsurance contracts			0							
17.	Amounts receivable relating to uninsured plans										
	Current federal and foreign income tax recoverable and interest thereon	_	0	0							
	Net deferred tax asset			15 , 165							
19.	Guaranty funds receivable or on deposit		0	0							
20.	Electronic data processing equipment and software		0	0							
21.	Furniture and equipment, including health care delivery assets										
22.	Net adjustment in assets and liabilities due to foreign exchange rates			0							
23.	Receivable from parent, subsidiaries and affiliates										
24.	Health care and other amounts receivable										
25.	Aggregate write-ins for other than invested assets		0								
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			486,789							
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts		0	0							
28.	Total (Lines 26 and 27)	1,983,038	2,469,827	486,789							
	DETAILS OF WRITE-INS										
1101.											
1102.											
1103.											
1198.	Summary of remaining write-ins for Line 11 from overflow page		0	0							
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0							
2501.	\(
2502.											
2503.											
2598.	Summary of remaining write-ins for Line 25 from overflow page		0	0							
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	0	0	0							

17

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

EXTENSION ENTROPERS		Total Members at End of						
Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months		
Health Maintenance Organizations	58,386	63,465	60,478	64,825	65,834	767,050		
Provider Service Organizations	0	0	0	0	0	0		
Preferred Provider Organizations	0	0	0	0	0	0		
4. Point of Service	0	0	0	0	0	0		
5. Indemnity Only	0	0	0	0	0	0		
Aggregate write-ins for other lines of business.	0	0	0	0	0	0		
7. Total	58,386	63,465	60,478	64,825	65,834	767,050		
DETAILS OF WRITE-INS								
0601.								
0602.								
0603.								
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0		
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0		

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying statutory financial statements of Aetna Better Health Inc. (a New Jersey corporation) (the "Company"), indirectly a wholly-owned subsidiary of CVS Health Corporation ("CVS Health"), have been prepared in conformity with accounting practices prescribed or permitted by the State of New Jersey Department of Banking and Insurance ("New Jersey Department") ("New Jersey Accounting Practices"). The New Jersey Department recognizes statutory accounting practices prescribed or permitted by the State of New Jersey for determining and reporting the financial condition and results of operations of an insurance company, which include accounting practices and procedures adopted by the National Association of Insurance Commissioners' ("NAIC") Accounting Practices and Procedures Manual ("NAIC SAP"). On November 28, 2018, CVS Health acquired Aetna Inc. ("Aetna") and at that date became the Company's ultimate parent (the "Aetna Acquisition").

A reconciliation of the Company's net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the State of New Jersey for the years ending December 31, 2019 and 2018 is as follows:

		SSAP#	F/S Page	F/S Line#	2019	2018
NET II	NCOME					
(1)	State basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ 12,221,636	\$ 17,263,819
(2)	State Prescribed Practices that increase/(decrease) NAIC SAP:	N/A	N/A	N/A		
(3)	State Permitted Practices that increase/(decrease) NAIC SAP:	N/A	N/A	N/A	-	_
					_	_
(4)	NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ 12,221,636	\$ 17,263,819
SURPL	IIS					
(5)	State basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 64,755,115	\$ 52,889,343
(6)	State Prescribed Practices that increase/(decrease) NAIC SAP:	N/A	N/A	N/A	_	_
					_	_
(7)	State Permitted Practices that increase/(decrease) NAIC SAP:	N/A	N/A	N/A		
(8)	NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$ 64,755,115	\$ 52,889,343

B. <u>Use of Estimates in the Preparation of the Financial Statements</u>

The preparation of these financial statements in conformity with New Jersey Accounting Practices requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses. Actual results could differ from those estimates.

C. Accounting Policies

The Company applies the following significant accounting policies:

(1) Cash, Cash Equivalents and Short-Term Investments

Cash, cash equivalents and short-term investments, consisting primarily of money market instruments and other debt issues with an original maturity of up to one year, are carried at amortized cost. Short-term investments consist primarily of investments purchased with an original maturity date of greater than three months but less than one year. Cash equivalents consist of highly liquid instruments, which mature within three months from the date of purchase. The carrying amount of cash, cash equivalents and short-term investments approximates fair value. Cash accounts with positive balances shall not be reported separately from cash accounts with negative balances. If in the aggregate, the reporting entity has a net negative cash balance, it shall be reported as a negative asset and shall not be recorded as a liability.

(2) Bonds

Bonds, which include special deposits, are carried at amortized cost except for those bonds with an NAIC designation of 3 through 6, which are carried at the lower of amortized cost or fair value. The amount carried at fair value is not material to the financial statements. Bond premiums and discounts are amortized using the scientific interest method. When quoted prices in active markets for identical assets are available, the Company uses these quoted market prices to determine the fair value of bonds. This is used primarily for U.S. government securities. In other cases where a quoted market price for identical assets in an active market is either not available or not observable, the Company estimates fair values using valuation methodologies based on available and observable market information or by using a matrix pricing model. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. The Company had no investments where fair value was determined using broker quotes or an internal analysis of financial performance and cash flow projections at December 31, 2019 and 2018. Bonds include all investments whose maturity is greater than one year when purchased. Loan-backed and structured securities are carried at amortized cost adjusted for unamortized premiums and discounts and are accounted for using the retrospective adjustment method. Premiums and discounts on loan-backed and structured securities are amortized using the scientific method over the estimated remaining term of the securities, adjusted for anticipated prepayments. All adjustments between amortized cost and carrying value are reflected in unrealized capital gains and losses and are reported as direct adjustments to surplus.

Bonds are recorded as purchases or sales on the trade date.

The Company periodically reviews its bonds to determine whether a decline in fair value below the carrying value is other-than-temporary. For bonds, other than loan-backed and structured securities ("LB&SS"), an other-than-temporary impairment ("OTTI") shall be recorded if it is probable that the Company will be unable to collect all amounts due according to the contractual terms in effect at the date of acquisition. Declines deemed to be OTTI in the cost basis are recognized as realized capital losses. Yield-related impairments are deemed other-than-temporary when the Company intends to sell an investment at the reporting date before recovery of the cost of the investment.

For LB&SS, the Company records OTTI when the fair value of the loan-backed or structured security is less than the amortized cost basis at the balance sheet date and (1) the Company intends to sell the investment, or (2) the Company does not have the intent and ability to retain the investment for the time sufficient to recover the amortized cost basis, or (3) the Company does not expect to recover the entire amortized cost basis of the security, even if it does not intend to sell the security and has the intent and ability to hold. If it is determined an OTTI has occurred because of (1) or (2), the amount of the OTTI is equal to the difference between the amortized cost and the fair value of the security at the balance sheet date and this difference is recorded as a realized capital loss. If it is determined an OTTI has occurred because of (3), the amount of the OTTI is equal to the difference between the amortized cost and the present value of cash flows expected to be collected, discounted at the loan-backed or structured security's effective interest rate and this difference is also accounted for as a realized capital loss.

The Company analyzes all relevant facts and circumstances for each investment when performing its analysis to determine whether an OTTI exists. Among the factors considered in evaluating whether a decline is other-than-temporary, management considers whether the decline in fair value results from a change in the quality of the investment security itself, whether the decline results from a downward movement in the market as a whole, the prospects for realizing the carrying value of the bond based on the investee's current and short-term prospects for recovery and other factors. The risks inherent in assessing the impairment of an investment include the risk that market factors may differ from the Company's expectations and the risk that facts and circumstances factored into its assessment may change with the passage of time. Unexpected changes to market factors and circumstances that were not present in past reporting periods may result in a current period decision to sell securities that were not other-than-temporarily-impaired in prior reporting periods.

- (3) The Company did not own any common stock at December 31, 2019 or 2018.
- (4) The Company did not own any preferred stock at December 31, 2019 or 2018.
- (5) The Company did not have any mortgage loans at December 31, 2019 or 2018.
- (6) The Company did not have any investments in subsidiaries, controlled or affiliated companies at December 31, 2019 or 2018.
- (7) The Company did not have any investments in any joint ventures, partnerships and limited liability companies at December 31, 2019 or 2018.
- (8) The Company did not have any derivatives at December 31, 2019 or 2018.
- (9) Aggregate Health Policy Reserves and Related Expenses

Premium deficiency reserves ("PDR") are recognized when it is probable that the expected future hospital and medical costs, including maintenance costs, will exceed anticipated future premiums and reinsurance recoveries on existing contracts. Where allowed, anticipated investment income is considered in the calculation of any PDR. For purposes of calculating a PDR, contracts are grouped in a manner consistent with the method of acquiring, servicing and measuring the profitability of such contracts.

NOTES TO FINANCIAL STATEMENTS

Unearned premium reserves ("UEP") are recognized for premiums that are recorded by the Company that have not been earned as of the statement date. The company had no UEP balances that were included in aggregate health policy reserves at December 31,2019 and 2018.

The Company is required to make premium rebate payments to customers that are enrolled under certain health insurance policies if specific minimum annual medical loss ratios ("MLR") were not met in the prior year. The Company's results for full year 2019 and 2018 include estimates of \$11,929,875 and \$11,437,653, respectively, of minimum MLR rebates, which were included in aggregate health policy reserves in the Statutory Statements of Liabilities and Capital and Surplus.

(10) Hospital and Medical Costs and Claims Adjustment Expenses and Related Reserves

Hospital and medical costs consist principally of fee-for-service medical claims and capitation costs. Claims unpaid and aggregate health claim reserves include the Company's estimate of payments to be made on claims reported but not yet paid and for health care services rendered to enrollees but not yet reported to the Company as of the Statutory Statements of Assets and Liabilities, Capital and Surplus date. Such estimates are developed using actuarial principles and assumptions, which consider, among other things, historical and projected claim submission and processing payment patterns, medical cost trends, historical utilization of health care services, claim inventory levels, medical inflation, contract requirement changes in membership and product mix, seasonality and other relevant factors. The Company reflects changes in estimates in hospital and medical costs in the Statutory Statements of Revenue and Expenses in the period they are determined. Capitation costs, which are recorded in hospital and medical expenses in the Statutory Statements of Revenue and Expenses, represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the medical services provided to the enrollee.

The Company uses the triangulation method to estimate reserves for claims incurred but not reported. The method of triangulation makes estimates of completion factors that are then applied to the total paid claims (net of coordination of benefits) to date for each incurral month. This provides an estimate of the total projected incurred claims and total amount outstanding or claims incurred but not reported (claims unpaid). For the most current dates of service where there is insufficient paid claim data to rely solely on the triangulation method, the Company examines cost and utilization trends as well as environmental factors, plan changes, provider contracts, changes in membership and/or benefits, and historical seasonal patterns to estimate the reserve required for these months.

Claims adjustment expenses, which include cost containment expenses, represent the costs incurred related to the claim settlement process such as costs to record, process and adjust claims. These expenses are included in the Company's management agreement with an affiliate described in Note 10.

(11) The Company has not modified its capitalization policy from the prior period.

(12) Pharmaceutical Rebate Receivables

The Company estimates pharmaceutical rebate receivables based upon historical payment trends, actual utilization and other variables. Pharmaceutical rebates for a quarter are billed to the vendor within one month of the completion of the quarter with any adjustment to previously recorded amounts reflected at the time of billing. The Company reports pharmaceutical rebate receivables as health care receivables. Pharmacy rebate receivables not in accordance with SSAP No. 84 – *Health Care and Government Insured Plan Receivables* or are over 90 days past due are nonadmitted. All rebates are processed and settled monthly with an affiliated entity, including adjustments to previously billed periods. The pharmaceutical rebate receivables are more fully discussed in Note 28.

(13) Premiums and Amounts Due and Unpaid

Premium revenue for prepaid health or dental care products is recognized as income in the month in which enrollees are entitled to health or dental care services. Premiums collected before the effective period are reported as premiums received in advance. Premiums related to unexpired contractual coverage periods are reported as unearned premiums in the Statutory Statements of Liabilities, Capital and Surplus (refer to discussion of aggregate health policy reserves and related expenses above).

Nonadmitted amounts consist of all premiums due and unpaid greater than 90 days past due, with the exception of amounts due under government insured plans, which may be admitted assets under certain circumstances. In addition, for any customer for which the premiums due and unpaid greater than 90 days past due is more than a de minimus portion of the entire balance of premiums due and unpaid for that customer, the entire balance of premiums due and unpaid for that customer is nonadmitted. Management also performs a specific review of accounts and based on the results of the review, additional amounts may be nonadmitted. Uncollectible amounts are generally written-off and charged to revenue in the period in which the customer reconciliations are completed and agreed to by the customer (retroactivity) or when the account is determined to be uncollectible by the Company.

(14) Investment Income Due and Accrued

Accrued investment income consists primarily of interest. Interest is recognized on an accrual basis and dividends are recorded as earned on the ex-dividend date. Due and accrued income is not recorded on: (a) bonds in default; and (b) bonds delinquent more than 90 days or where collection of interest is improbable. At December 31, 2019 and 2018, the Company did not have any nonadmitted investment income due and accrued.

NOTES TO FINANCIAL STATEMENTS

(15) Covered and Uncovered Expenses and Related Liabilities

Covered expenses and related liabilities represent costs for health care expenses for which a member is not responsible in the event of the insolvency of the Company. Uncovered expenses and related liabilities represent costs to the Company for health care services that are the obligation of the Company and for which a member may also be liable in the event of the Company's insolvency.

(16) Fees Paid to the Federal Government by Health Insurers

SSAP No. 106 - Affordable Care Act Section 9010 Assessment ("SSAP No. 106") required (1) that the health insurer fee be recognized in full on January 1 of the fee year (the calendar year in which the assessment must be paid to the federal government), in the operating expense category of insurance taxes, licenses and fees, excluding federal income taxes and (2) that in each data year preceding a fee year a reporting entity pro-ratably accrue by reclassifying from unassigned funds (surplus) to aggregate write-ins for special surplus funds an amount equal to its estimated subsequent fee year assessment. This reclassification has no impact on total capital and surplus and is reversed in full on January 1 of the fee year. On January 22, 2018, Public Law No: 115-120 was signed into law and it imposes a moratorium on the health insurer fee for calendar year 2019. As interpreted in INT 18-02: ACA Section 9010 Assessment Moratoriums, because there was not an ACA Section 9010 fee due in September 2019, there was not an accrual of a liability on January 1, 2019 based on 2018 data year net written premiums. Accrual of a liability on January 1, 2020 for the ACA Section 9010 assessment based on 2019 data year net written premiums and the reclassification from unassigned funds (surplus) to aggregate write-ins for special surplus funds equal to the estimated 2020 fee year assessment accrued in data year 2019 will both continue as prescribed under SSAP No. 106. See Note 22 for disclosure of all amounts related to the health insurer fee for the Company.

(17) Federal and State Income Taxes

Aetna and its wholly-owned subsidiaries are included in the consolidated federal income tax return of its parent company, CVS Health, pursuant to the terms of a tax sharing agreement (and a Supplemental Tax Sharing Agreement where applicable) between CVS Health and the Company.

In accordance with the agreements, the Company's current federal and state income tax provisions are generally computed as if the Company were filing a separate federal and state income tax return; current income tax benefits, including those resulting from net operating losses, are recognized to the extent expected to be realized in the consolidated return. Pursuant to the agreements, the Company has the enforceable right to recoup federal and state income taxes paid in prior years in the event of future net losses, which it may incur, or to recoup its net losses carried forward as an offset to future net income subject to federal and state income taxes.

Income taxes are accounted for under the asset and liability method. Deferred income tax assets ("DTAs") and liabilities ("DTLs") represent the expected future tax consequences of temporary differences generated by statutory accounting as defined in SSAP No. 101 - *Income Taxes*. DTAs and DTLs are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. DTAs and DTLs are computed by means of identifying temporary differences which are measured using a balance sheet approach whereby statutory and tax basis balance sheets are compared. Current income tax recoverables include all current income taxes, including interest, reasonably expected to be recovered in a subsequent accounting period.

Pursuant to SSAP No. 101, gross DTAs are first reduced by a statutory valuation allowance adjustment to an amount that is more likely than not to be realized ("adjusted gross DTAs"). Adjusted gross DTAs are then admitted in an amount equal to the sum of paragraphs a. b. and c. below:

- a. Federal income taxes paid in prior years that can be recovered through loss carrybacks for existing temporary differences that reverse during a timeframe corresponding with Internal Revenue Code ("IRC") tax loss carryback provisions.
- b. The amount of adjusted gross DTAs, after the application of paragraph a. above, expected to be realized within the applicable period and that is no greater than the applicable percentage as determined using the applicable Realization Threshold Limitation Table. The applicable period refers to the number of years in which the DTA will reverse in the Company's tax return and the applicable percentage refers to the percentage of the Company's statutory capital and surplus as required to be shown on the statutory balance sheet adjusted to exclude any net DTAs, electronic data processing equipment and operating system software and any net positive goodwill ("Stat Cap ExDTA").

The Realization Threshold Limitation Tables allow DTAs to be admitted based upon either realization within 3 years and 15% of Stat Cap ExDTA, 1 year and 10% of Stat Cap ExDTA, or no DTA admitted pursuant to this paragraph b. In general, the Realization Threshold Limitation Tables allow the Company to admit more DTAs if total DTAs as reported by the Company are a smaller percentage of statutory capital and surplus.

c. The amount of gross DTAs, after the application of paragraphs a. and b. above that can be offset against existing gross DTLs. In applying this offset, the Company considers the character (i.e. ordinary versus capital) of the DTAs and DTLs such that offsetting would be permitted in the tax return under existing enacted federal income tax laws and regulations and the reversal patterns of temporary differences.

NOTES TO FINANCIAL STATEMENTS

Changes in DTAs and DTLs are recognized as a separate component of gains and losses in surplus ("Change in net deferred income tax") except to the extent allocated to changes in unrealized gains and losses. Changes in DTAs and DTLs allocated to unrealized gains and losses are netted against the related changes in unrealized gains and losses and are reported as "Change in net unrealized capital gains (losses)", also a separate component of gains and losses in surplus.

The Company is subject to state income taxes in the State of New Jersey. State income tax expense is recorded in general administrative expenses in the Statutory Statements of Revenue and Expenses. For the years ended December 31, 2019 and 2018, the Company incurred state income tax (benefits)/expenses of (\$333,733) and \$3,012,049, respectively. There were no state income tax payables at December 31, 2019 and \$1,613,287 of state income tax payables at December 31,2018 included in general expenses due or accrued in the Statutory Statements of Liabilities, Capital and Surplus. The Company had \$194,217 of state income tax receivables at December 31, 2019 and there were no state income tax receivables at December 31, 2018. These balances were included as aggregate write-ins for other than invested assets in the Statutory Statements of Assets.

(18) Reinsurance

In the normal course of business, the Company seeks to reduce the loss that may arise from catastrophes or other events that cause unfavorable underwriting results and to help balance its risks and capital by reinsuring certain levels of risk with other insurance enterprises. The reinsurance coverage does not relieve the Company of its primary obligations. Reinsurance premiums and reserves related to reinsured business are accounted for on a basis consistent with those used in accounting for the original policies issued and the terms of the reinsurance contracts. Premiums ceded for medical losses and the related unpaid reserves have been reported as reductions of these items. The reinsurance agreements are more fully discussed in Note 23.

D. Going Concern

As of February 28, 2020, management evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern and management has determined that it is not probable that the Company will be unable to meet its obligations as they become due within one year after the financial statements are available to be issued. Management will continuously evaluate the Company's ability to continue as a going concern and will take appropriate action and will make appropriate disclosures if there is any change in any condition or events that would raise substantial doubt about the Company's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

The Company did not have any accounting changes or correction of errors in the years ended December 31, 2019 and 2018.

3. Business Combinations and Goodwill

The Company was not a part of any business combinations that involved the statutory purchase method, a statutory merger, an assumption reinsurance, or an impairment loss in the years ending December 31, 2019 and 2018.

Discontinued Operations

The Company did not have any discontinued operations in the years ending December 31, 2019 and 2018.

5. <u>Investments</u>

- A. The Company did not have any mortgage loans, including Mezzanine Real Estate Loans, at December 31, 2019 and 2018.
- B. The Company did not have any debt restructuring in the years ending December 31, 2019 and 2018.
- C. The Company did not have any reverse mortgages at December 31, 2019 or 2018.

D. Loan-Backed Securities

- (1) Prepayment assumptions for single class and multi-class mortgage-backed/loan-backed securities were obtained from industry market sources.
- (2) The Company did not recognize any other-than-temporary impairments ("OTTI") on loan-backed and structured securities in which the Company had the (1) intent to sell, (2) did not have the intent and ability to retain for a period of time sufficient to recover the amortized cost basis or (3) present value of cash flows expected to be collected is less than the amortized cost basis of the securities in accordance with SSAP No. 43R Loan-Backed and Structured Securities ("SSAP No. 43R") at December 31, 2019.
- (3) The Company had no recognized OTTI on loan-backed and structured securities currently held, in which the present value of cash flows expected to be collected is less than the amortized cost basis at December 31, 2019.

(4) The Company's unrealized loss position on loan-backed and structured securities held by the Company at December 31, 2019 is as follows:

a.	The aggregate amount of unrealized losses:	
	1. Less than 12 months	-
	2. 12 Months or Longer	\$ (4,405)
b.	The aggregate related fair value of securities with unrealized losses:	
	1. Less than 12 months	-
L	2. 12 Months or Longer	\$ 495,596

- (5) The Company has reviewed the loan-backed and structured securities in accordance with SSAP No. 43R in the table above and has concluded that these are performing assets generating investment income to support the needs of the business. Furthermore, the Company has no intention to sell the securities at December 31, 2019 before their cost can be recovered and does have the intent and ability to retain the securities for the time sufficient to recover the amortized cost basis; therefore, no OTTI write-down to fair value was determined to have occurred on these securities.
- E. The Company had no dollar repurchase agreements and/or securities lending transactions at December 31, 2019.
- F. The Company did not have any repurchase agreements transactions accounted for as secured borrowing at December 31, 2019.
- G. The Company did not have any reverse repurchase agreements transactions accounted for as secured at December 31, 2019.
- H. The Company did not have any repurchase agreements transactions accounted for as a sale at December 31, 2019.
- I. The Company did not have any reverse repurchase agreements transactions accounted for as a sale at December 31, 2019.
- J. The Company did not have any real estate at December 31, 2019.
- K. The Company did not have any low-income housing tax credits at December 31, 2019 or 2018.
- L. Restricted Assets
 - (1) Restricted assets (including pledged):

	1	2	3	4	5	6	7
Restricted Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Gross (Admitted & Nonadmitted) Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a. Restricted Asset Category: Subject to contractual obligation for which liability is not shown	_		_	_		0.0	0.0
b. Collateral held under security lending agreements	_		_	_	_	0.0	0.0
c. Subject to repurchase agreements	_		_	_	_	0.0	0.0
d. Subject to reverse repurchase agreements	_		_	_	_	0.0	0.0
e. Subject to dollar repurchase agreements	_		_	_	_	0.0	0.0
f. Subject to dollar reverse repurchase agreements	_		_	_	_	0.0	0.0
g. Placed under option contracts	_		_	_	_	0.0	0.0
h. Letter stock or securities restricted as to sale - excluding FHLB capital stock	_		_	_	_	0.0	0.0
i. FHLB capital stock	_		_	_	_	0.0	0.0
j. On deposit with states	\$ 52,047,754	\$ 41,415,991	\$ 10,631,763	\$ —	\$ 52,047,754	35	35
k. On deposit with other regulatory bodies	_		_	_	_	0.0	0.0
Pledged collateral to FHLB (including assets backing funding agreements)	_		_	_	_	0.0	0.0
m. Pledged as collateral not captured in other categories	_		_	_	_	0.0	0.0
n. Other restricted assets	_		_	_	_	0.0	0.0
o. Total Restricted Assets	\$ 52,047,754	\$ 41,415,991	\$ 10,631,763	\$ —	\$ 52,047,754	35	35

(a) Column 1 divided by Asset Page, Column 1, Line 28 (b) Column 5 divided by Asset Page, Column 3, Line 28

NOTES TO FINANCIAL STATEMENTS

- (2) The Company did not have any assets pledged as collateral not captured in other categories at December 31, 2019 or 2018.
- (3) The Company did not have any other restricted assets at December 31, 2019 or 2018.
- (4) The Company did not have any collateral received and reflected within its financial statements at December 31, 2019.
- M. The Company did not have any working capital finance investments at December 31, 2019.
- N. The Company did not have any offsetting and netting of derivative, repurchase and reverse repurchase, and securities borrowing and securities lending assets or liabilities at December 31, 2019.
- O. The Company did not have any 5GI securities at December 31, 2019 or 2018.
- P. The Company did not have any short sales within the reporting period.
- Q. Prepayment Penalty and Acceleration Fees at December 31, 2019.

Prepayment Penalty and Acceleration Fees

	Genera	al Account
1. Number of CUSIPs		1
2. Aggregate Amount of Investment Income	\$	10,610

6. Joint Ventures, Partnerships, and Limited Liability Companies

- A. The Company did not have any joint ventures, partnerships, or limited liability companies that exceeded 10% of its admitted assets at December 31, 2019 or 2018.
- B. The Company does not have any impaired investments in joint ventures, partnerships, or limited liability companies at December 31, 2019 or 2018.

7. Investment Income

A. Due and accrued income was excluded from surplus on the following bases:

Bonds - where collection of interest is uncertain.

B. There was no amount excluded at December $31,\,2019$ or 2018.

8. Derivative Instruments

The Company did not have any derivative instruments at December 31, 2019 or 2018.

9. Income Taxes

A.

(1) The components of the net DTAs recognized in the Company's Statutory Statements of Assets and Liabilities, Capital and Surplus are as follows:

			12/31/2019			12/31/2018			Change			
		(1)	(2)	(3) (Col. 1 + 2)	(4)	(5)	(6) (Col. 4 + 5)	(7) (Col. 1 - 4)	(8) (Col. 2 - 5)	(9) (Col. 7 + 8)		
		Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total		
(a)	Gross Deferred Tax Assets	\$ 598,969	\$ 187,148	\$ 786,117	\$1,383,282	\$ 133,303	\$1,516,585	\$ (784,313)	\$ 53,845	\$ (730,468)		
(b)	Statutory Valuation Allowance Adjustment	_	_	_	_	_	_	_	_	_		
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	598,969	187,148	786,117	1,383,282	133,303	1,516,585	(784,313)	53,845	(730,468)		
(d)	Deferred Tax Assets Nonadmitted	_	40,294	40,294	_	55,459	55,459	_	(15,165)	(15,165)		
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	598,969	146,854	745,823	1,383,282	77,844	1,461,126	(784,313)	69,010	(715,303)		
(f)	Deferred Tax Liabilities	82,100	146,854	228,954	48,231	68,538	116,769	33,869	78,316	112,185		
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ 516,869	s —	\$ 516,869	\$1,335,051	\$ 9,306	\$1,344,357	\$ (818,182)	\$ (9,306)	\$ (827,488)		

(2) The amount of admitted gross DTAs admitted under each component of SSAP No. 101:

NOTES TO FINANCIAL STATEMENTS

			12/31/2019			12/31/2018				
		(1)	(2)	(3) (Col. 1 + 2)	(4)	(5)	(6) (Col. 4 + 5)	(7) (Col. 1 - 4)	(8) (Col. 2 - 5)	(9) (Col. 7 + 8)
		Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total
Adm SSA	ission Calculation Components P No. 101									
(a)	Federal Income Taxes Paid In Prior Years Recoverable Through Loss Carrybacks.	\$ 597,059	s —	\$ 597,059	\$1,374,519	\$ 9,306	\$1,383,825	\$ (777,460)	\$ (9,306)	\$ (786,766)
	Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold									
(b)	Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	1,910	_	1,910	8,763	_	8,763	(6,853)	_	(6,853)
	Adjusted Gross Deferred Tax Assets Expected to be Realized Following the Balance Sheet Date.	1,910	_	1,910	8,763	_	8,763	(6,853)	_	(6,853)
	2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.			9,635,737			7,731,748			1,903,989
(c)	Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	_	146,854	146,854	_	68,538	68,538	_	78,316	78,316
(d)	Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	\$ 598,969	\$ 146.854	\$ 745,823	\$1 202 202	\$ 77.944	\$1,461,126	\$ (784,313)	\$ 69,010	\$ (715,303)

(3)

			2019	2018
(a)	Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount.		385 %	339 %
(1-)	Amount Of Adjusted Conital And Cumbus Head To Determine Beassers, David And Threehold Limitation In 2(h)2 Above	e.	(4.339.346.6	51 544 006

(4) The impact of tax planning strategies is as follows:

	_									
		12/31/2019 12/31/2018								
		(1)		(2)		(3)	(4)	П	(5)	(6)
		Ordinary		Capital		Ordinary	Capital		(Col. 1 - 3) Ordinary	(Col. 2 - 4) Capital
Impact of Tax Planning Strategies:										
(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage.										
1. Adjusted Gross DTAs amount from Note 9A1(c)	\$	598,969	\$	187,148	\$	1,383,282	\$ 133,303	\$	(784,313)	\$ 53,845
Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies		— %		— %		— %	— º/	ó	— %	— %
3. Net Admitted Adjusted Gross DTAs amount from Note 9A1(e)		598,969		146,854		1,383,282	77,844		(784,313)	69,010
4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies		— %		— %		— %	%	ó	— %	— %

⁽b) Do the Company's tax-planning strategies include the use of reinsurance?

Yes [] No [X]

- B. There are no DTLs that were not recognized at December 31, 2019 or 2018.
- C. Current income taxes incurred consist of the following major components:

	NOTES TO FINANCIAL ST	AILIVILIAI	<u> </u>	
		(1)	(2)	(3)
1. Cui	rent Income Tax	12/31/2019	12/31/2018	(Col. 1 - 2)
(a)	Federal	\$ 681,845	\$ 4,747,524	\$ (4,065,679)
(b)	Foreign		_	_
(c)	Subtotal	681,845	4,747,524	(4,065,679)
(d)	Federal income tax on net capital gains	(14,208)	(45,204)	30,996
(e)	Utilization of capital loss carry-forwards			_
(f)	Other		_	_
(g)	Federal and foreign income taxes incurred	667,637	4,702,320	(4,034,683)
2. Det	erred Tax Assets:			
(a)	Ordinary:			
	(1) Discounting of unpaid losses	190,993	876,265	(685,272)
	(2) Unearned premium reserve	_	_	_
	(3) Policyholder reserves	_	_	_
	(4) Investments	_	_	_
	(5) Deferred acquisition costs	_	_	_
	(6) Policyholder dividends accrual	_	_	_
	(7) Fixed Assets	_	_	_
	(8) Compensation and benefits accrual	_	_	_
	(9) Pension accrual	_	_	
	(10) Receivables - nonadmitted	407,976	507,017	(99,041)
	(11) Net operating loss carry-forward	407,570	307,017	(22,041)
	(12) Tax credit carry-forward	_	_	_
	(13) Other (including items <5% of total ordinary tax assets)	_	_	_
	(99) Subtotal	598,969	1,383,282	(784,313)
(b)	Statutory valuation allowance adjustment	398,909	1,363,262	(764,313)
(b)	Nonadmitted	_	_	_
(c)		500.000	1 292 292	(794 212)
(d)	Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	598,969	1,383,282	(784,313)
(e)	Capital:	107.140	122 202	52.045
	(1) Investments	187,148	133,303	53,845
	(2) Net capital loss carry-forward	_	_	_
	(3) Real estate	_	_	_
	(4) Other (including items <5% of total ordinary tax assets)		_	_
	(99) Subtotal	187,148	133,303	53,845
(f)	Statutory valuation allowance adjustment	_	_	_
(g)	Nonadmitted	40,294	55,459	(15,165)
(h)	Admitted capital deferred tax assets (2e99 - 2f - 2g)	146,854	77,844	69,010
(i)	Admitted deferred tax assets (2d + 2h)	745,823	1,461,126	(715,303)
3. Def	Ferred Tax Liabilities:			
(a)	Ordinary:			
	(1) Investments	41,907	_	41,907
	(2) Fixed assets	_	_	_
	(3) Deferred and uncollected premium	_	_	_
	(4) Policyholder reserves	_	_	_
	(5) Other (including items <5% of total ordinary tax liabilities)	40,193	48,231	(8,038)
	(99) Subtotal	82,100	48,231	33,869
(b)	Capital:			
	(1) Investments	146,854	68,538	78,316
	(2) Real estate	_		
	(3) Other (including items <5% of total capital tax liabilities)	_	_	_
	(99) Subtotal	146,854	68,538	78,316
(c)	Deferred tax liabilities (3a99 + 3b99)	228,954	116,769	112,185
	deferred tax assets/liabilities (2i - 3c)	\$ 516,869		
		. 210,507	. 1,5,557	. (027,.00)

The change in net deferred income taxes is comprised of the following:

	 12/31/2019	12/31/2018	Change
Total Deferred Tax Assets	\$ 786,117 \$	1,516,585 \$	(730,468)
Total Deferred Tax Liabilities	 (228,954)	(116,769)	(112,185)
Net Deferred Tax Assets/(Liabilities)	557,163	1,399,816	(842,653)
Tax Effect of Unrealized Gains/(Losses)			
Change in Net Deferred Income Tax		\$	(842,653)

There was no valuation allowance adjustment to gross DTAs as of December 31, 2019 or 2018. The Company bases its estimates of the future realization of DTAs primarily on historic taxable income and existing DTLs.

D. The provision for federal income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference were as follows:

	12/31/2019	Effective Tax Rate	12/31/2018	Effective Tax Rate
Provision computed at statutory rate	\$ 2,706,746	21.0 %	\$ 4,612,891	21.0 %
Health Insurer Fee	_	0.0 %	598,088	2.7 %
Transfer Pricing Adjustment	(1,187,370)	(9.2)%	(860,583)	(3.9)%
Tax-Exempt Interest	(10,019)	(0.1)%	(56,187)	(0.3)%
Change in Nonadmitted Assets	99,041	0.8 %	(211,968)	(1.0)%
Prior Year True-Up	(85,904)	(0.7)%	294,433	1.3 %
Change in Valuation Allowance Adjustment	_	0.0 %	_	0.0 %
Expiration of NOL	_	0.0 %	_	0.0 %
Impact on Deferred Tax for Enacted Rate Change	_	0.0 %	_	0.0 %
Contribution of Intangibles to JV	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
[add'l breakout line for other significant items]	_	0.0 %	_	0.0 %
Other	 (12,204)	(0.1)%	(77,096)	(0.4)%
Total	\$ 1,510,290	11.7 %	\$ 4,299,578	19.6 %
Federal and foreign income taxes incurred	\$ 667,637	5.3 %	\$ 4,702,320	21.5 %
Change in net deferred income taxes	842,653	6.5 %	(402,742)	(1.8)%
Total statutory income taxes	\$ 1,510,290	11.7 %	\$ 4,299,578	19.6 %

The transfer pricing adjustment allows taxpayers to apply different methods to price current period intercompany services at arm's length prices (i.e., prices at which unrelated entities would be willing to transact), which results in a permanent deduction for tax reporting purposes.

E.

- (1) At December 31, 2019 and 2018, the Company had no net capital loss or net operating loss carryforwards for tax purposes.
- (2) The amount of federal income taxes incurred that is available for recoupment in the event of future net losses is as follows:

Year	 Ordinary	Capital		Total
2019	\$ 876,739	\$	— \$	876,739
2018 stub 2	388,755		_	388,755
2018 stub 1	 N/A		_	
Total	\$ 1,265,494	\$	— \$	1,265,494

(3) The Company did not report any deposits as admitted assets under Internal Revenue Code Section 6603 at December 31, 2019 and 2018.

F

(1) At December 31, 2019, the Company's Federal Income Tax Return was consolidated with the following entities:

@ Credentials Inc. ACCENDO INSURANCE COMPANY ACS ACOCO CORP. Active Health Management, Inc. Adminco, Inc. Administrative Enterprises, Inc.

Aetna Better Health of Florida, Inc. (F/K/A Coventry Health Care of Florida, Inc.) ADVANCED CARE SCRIPTS, INC

Aetna Better Health Inc. (Georgia) Aetna Better Health Inc. (IL) Aetna Better Health Inc. (NJ) Aetna Better Health Inc. (NY) Aetna Better Health Inc. (OH) Aetna Better Health Inc. (Tennessee) Aetna Better Health of California, Inc. Aetna Better Health of Kansas Inc Aetna Better Health of Kentucky Insurance Co. Aetna Better Health of Michigan, Inc Aetna Better Health of Missouri LLC Aetna Better Health of Nevada Inc. Aetna Better Health of North Carolina, Inc. Aetna Better Health of Oklahoma Inc. Aetna Better Health of Texas, Inc. Aetna Better Health of Washington, Inc. Aetna Better Health, Inc. (LA) Aetna Better Health, Inc. (Connecticut)

Aetna Better Health, Inc. (PA) Aetna Dental Inc. (NJ) Aetna Dental of California, Inc. Aetna Dental Inc. (Texas)

Aetna Florida, Inc. Aetna Health Inc. (Connecticut) Aetna Health Inc. (Florida) Aetna Health Inc. (Georgia) Aetna Health Inc. (LA) Aetna Health Inc. (Maine) Aetna Health of Michigan (FKA Aetna Health Inc. (MI)) Aetna Health Inc. (New Jersey) Aetna Health Inc. (NY) Aetna Health Inc. (Pennsylvania) Aetna Health Insurance Co.

Aetna Health Inc. (Texas) Aetna Health of California Inc. Aetna Health Insurance Company of New York

Aetna Health of Iowa, Inc Aetna Health of Ohio, Inc. (F/K/A Aetna Better Health of Iowa, Inc.)

Aetna Health of Utah. Inc. Aetna HealthAssurance Pennsylvania, Inc. Aetna Integrated Informatics, Inc. Aetna Inc.

Aetna International Inc. Aetna Ireland Inc.

Aetna Life & Casualty (Bermuda) Limited Aetna Risk Assurance Company of Connecticut Aetna Student Health Agency, Inc. ALABAMA CVS PHARMACY, L.L.C. APRIA FINANCE HOLDINGS. INC. American Health Holding, Inc. BRUIN ACOUISITION CO., INC. AUSHC Holdings, Inc. (CT)

bswift, LLC Carefree Insurance Services, Inc CAREMARK ULYSSES HOLDING CORP. Claims Administration Corporation

CONNECTICUT CVS PHARMACY, L.L.C. CORAM ALTERNATE SITE SERVICES, INC. CORAM CLINICAL TRIALS, INC.

CORAM HEALTHCARE CORPORATION OF ALABAMA CORAM HEALTHCARE CORPORATION OF FLORIDA

CORAM HEALTHCARE CORPORATION OF GREATER D.C. CORAM HEALTHCARE CORPORATION OF GREATER NEW YORK CORAM HEALTHCARE CORPORATION OF INDIANA CORAM HEALTHCARE CORPORATION OF MASSACHUSETTS CORAM HEALTHCARE CORPORATION OF MISSISSIPPI CORAM HEALTHCARE CORPORATION OF NEVADA CORAM HEALTHCARE CORPORATION OF NORTH TEXAS CORAM HEALTHCARE CORPORATION OF NORTHERN

CALIFORNIA

CORAM HEALTHCARE CORPORATION OF SOUTHERN FLORIDA

CORAM HEALTHCARE CORPORATION OF SOUTHERN **CALIFORNIA**

CORAM HEALTHCARE CORPORATION OF UTAH

Coventry Consumer Advantage, Inc. Coventry Health and Life Insurance Company Coventry Health Care National Accounts, Inc. Coventry Health Care National Network, Inc. Coventry Health Care of Illinois, Inc. Coventry Health Care of Kansas, Inc. Coventry Health Care of Missouri, Inc. Coventry Health Care of Nebraska, Inc. Coventry Health Care of Virginia, Inc.

Coventry Health Care of West Virginia, Inc. Coventry Health Care Workers Compensation, Inc. Coventry Health Plan of Florida, Inc. Coventry HealthCare Management Corporation

Coventry Prescription Management Services, Inc. Coventry Rehabilitation Services, Inc.

Coventry Transplant Network, Inc. CVS AOC Corporation CVS ARCLIGHT, INC. CVS CAREMARK INDEMNITY LTD. CVS FOREIGN, INC. CVS INTERNATIONAL, L.L.C. CVS PHARMACY, INC. CVS PR CENTER, INC. CVS RX SERVICES, INC. CVS WWRE, INC.

DELAWARE CVS PHARMACY, L.L.C. Delaware Physicians Care, Inc. E.T.B., INC. Echo Merger Sub, Inc

ECKERD CORPORATION OF FLORIDA, INC. EVERGREEN PHARMACEUTICAL OF CALIFORNIA, INC.

First Health Group Corp. First Health Life and Health Insurance Company First Script Network Services, Inc. Florida Health Plan Administrators, LLC FOCUS Healthcare Management, Inc. Group Dental Service of Maryland, Inc. Health and Human Resource Center, Inc. Group Dental Service, Inc.

Health Data & Management Solutions, Inc. Health Re, Inc. HOLIDAY CVS L.L.C. Health Assurance Pennsylvania Inc. IOWA CVS PHARMACY, L.L.C. JEC FUNDING, INC.

NOTES TO FINANCIAL STATEMENTS

JHC ACQUISITION, LLC

Managed Care Coordinators, Inc.

MASSACHUSETTS CVS PHARMACY, INC.

MELVILLE REALTY CO., INC.

Mental Health Network of New York IPA, Inc.

MetraComp, Inc.
MHNet of Florida, Inc.

MinuteClinic Physician Practice of Texas NCS HEALTHCARE OF KENTUCKY, INC.

NEIGHBORCARE HOLDINGS, INC.
NEIGHBORCARE SERVICES CORPORATION

Niagara Re, Inc.

OKLAHOMA CVS PHARMACY, L.L.C.

OMNICARE, INC.
PayFlex Systems USA, Inc.

Performax, Inc. PrimeNet, Inc.

Professional Risk Management, Inc.

RETRAC, INC.

Schaller Anderson Medical Administrators Inc

SKY ACOUISITION LLC

TENNESSEE CVS PHARMACY, L.L.C.
U.S. Health Care Properties, Inc.
VIRGINIA CVS PHARMACY, L.L.C.

KENTUCKY CVS PHARMACY, L.L.C.

MARYLAND CVS PHARMACY, L.L.C.

MED WORLD ACQUISITION CORP.

Mental Health Associates, Inc.

Meritain Health, Inc.

MHNet Life and Health Insurance Company

MINUTECLINIC DIAGNOSTIC OF ILLINOIS, L.L.C. MinuteClinic Telehealth Services of Texas Association

NCS HEALTHCARE, LLC

NEIGHBORCARE PHARMACY SERVICES, INC.

NEIGHBORCARE, INC.

NORTH CAROLINA CVS PHARMACY, L.L.C.

OMNICARE HOLDING COMPANY

PayFlex Holdings, Inc.

PENNSYLVANIA LIFE INSURANCE COMPANY

Precision Benefit Services, Inc. Prodigy Health Group, Inc. Resources for Living, LLC

RICHMOND HEIGHTS ACQUISITION CORP. SILVERSCRIPT INSURANCE COMPANY

T2 MEDICAL, INC.
The Vasquez Group, Inc.
UAC HOLDING, INC.
Work & Family Benefits, Inc.

- (2) As explained in Note 1, the Company participates in a tax sharing agreement with its parent and affiliates.
- G. The Company does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.
- H. The Company was not subject to the Repatriation Transition Tax at December 31, 2019.
- I. The Company did not recognize any gross Alternative Minimum Tax credit at December 31, 2019.
- 10. Information Concerning Parent, Subsidiaries, Affiliates, and Other Related Parties

A., B. and C.

The Company did not have any transactions during 2019 or 2018 with its parent, subsidiaries and affiliates excluding reinsurance transactions and non-insurance transactions involving less the ½ of 1% of the Company's total admitted assets.

D. At December 31, 2019 and 2018, the Company had the following amounts due to and due from affiliates, which exclude amounts related to pharmacy rebate transactions as discussed more fully in Note 28 and the Company's reinsurance agreements if applicable.

	December 31	
	2019	2018
Amounts due to affiliates		
Aetna Health Management, LLC	\$ 271,040 \$	_
Aetna Inc.	_	7,010,185
Aetna Medicaid Adminstrators LLC	_	2,752,297
Aetna Life Insurance Company	 	302,938
Total due to affiliates	\$ 271,040 \$	10,065,420
	December 31	
	2019	2018
Amounts due from affiliates		
Aetna Medicaid Administrators, LLC	\$ 4,670,997 \$	
Total due to affiliates	\$ 4,670,997 \$	

The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter.

E. The Company does not have any guarantees or undertakings, written or otherwise at December 31, 2019.

NOTES TO FINANCIAL STATEMENTS

F. As of and for the years ended December 31, 2019 and 2018, the Company had the following significant transactions with affiliates:

The Company and Aetna Medicaid Administrators LLC ("AMA") are parties to an administrative services agreement, under which AMA and certain of its affiliates provides certain administrative services, including cash management and accounting and processing of premiums and claims. Under this agreement, the Company will remit a percentage of its earned premium revenue, as applicable, to AMA as a fee. For these services, the Company was charged \$41,391,206 and \$33,742,462 in 2019 and 2018, respectively.

The Company, AMA and Aetna Health Management, LLC ("AHM"), indirectly a wholly-owned subsidiary of CVS Health, entered into a plan joinder agreement. Under this agreement, AHM has contracted with Caremark PCS Health, LLC ("Caremark"), an affiliate, to deliver pharmacy benefit management services to the Company. The Company will make payments to AMA in accordance with the administrative services agreement.

The Company has an insolvency agreement with Aetna Health Insurance Company ("AHIC"), a wholly-owned subsidiary of Aetna. This agreement provides that in the event that the Company ceases operations or becomes insolvent, AHIC will continue to pay benefits for any members confined as inpatients on the date of insolvency until their discharge. This agreement also provides that AHIC will continue benefits for any member until the end of the contract period for which premium has been paid, but for no longer than thirty-one days. AHIC will also make available to members, for a period of thirty-one days, replacement insurance policies.

As explained in Note 1, Aetna and its wholly-owned subsidiaries, including the Company, participate in a tax sharing agreement with CVS Health. All federal income tax receivables/payables are due from/due to CVS Health.

- G. All outstanding shares of the Company are owned by Aetna Health Holdings, LLC, whose ultimate parent is CVS Health.
- H. At December 31, 2019, the Company did not own shares of an upstream intermediate entity or CVS Health, either directly or indirectly.
- I. At December 31, 2019, the Company did not hold any investments in any subsidiary, controlled or affiliated ("SCA") entity that exceeded 10% of the Company's admitted assets.
- J. At December 31, 2019, the Company did not hold any investments in any impaired SCA entity.
- K. At December 31, 2019, the Company did not hold any investments in any foreign insurance subsidiaries.
- L. At December 31, 2019, the Company did not hold any investments in a downstream noninsurance holding company.
- M. At December 31, 2019, the Company did not have any SCA investments.
- N. At December 31, 2019, the Company did not have any investments in an insurance SCA.
- O. The Company did not have any SCA or SSAP No. 48 entity investments where the Company's share of losses in the SCA exceeds its investment in the SCA.

11. <u>Debt</u>

- A. The Company did not have any items related to debt, including capital notes at December 31, 2019.
- B. The Company did not have any Federal Home Loan Bank agreements at December 31, 2019.
- 12. <u>Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans</u>

The Company did not have a retirement plan, deferred compensation plan, or other postretirement benefit plan at December 31, 2019 or 2018.

- 13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations
 - (1) The Company had 10,000 shares of common capital stock authorized, with 100 shares issued and outstanding with a par value of \$0 per share at December 31, 2019 and 2018.
 - (2) The Company had no shares of preferred stock issued and outstanding at December 31, 2019 and 2018.
 - (3) Dividend Restrictions

NOTES TO FINANCIAL STATEMENTS

Under the laws of the State of New Jersey, the Company shall not pay out dividends without the prior written approval of the New Jersey Department. The New Jersey Department may disapprove the dividend request for a period of 30 days after the receipt of notification.

Pursuant to New Jersey statute, no domestic insurer shall pay an extraordinary distribution to its shareholders until: (a) thirty days after the New Jersey Department has received notice of the declaration thereof and has not within such period disapproved such payment, or (b) the New Jersey Department approves such payment within the 30-day period. An extraordinary dividend or distribution is any dividend or distribution of cash or other property, whose fair market value together with that of other dividends or distributions made within the preceding twelve months exceeds the greater of: (a) 10% of the Company's surplus as regards to policyholders as of the 31st day of December next preceding, or (b) the net income, not including realized gains, for the 12 month period ending the 31st day of December next preceding, but shall not include pro rata distributions of any class of the Company's own securities.

(4) The Company did not pay any dividends in 2019 or 2018.

The Company did not receive any capital contributions or pay any returns of capital in 2019 or 2018.

- (5) At December 31, 2019 and 2018, there was \$12,215,107 and \$17,263,819, respectively, of the Company's profits that may be paid as ordinary dividends to its shareholder without prior approval from the New Jersey Department. There were no restrictions placed on the Company's surplus, including for whom the surplus was being held at December 31, 2019 or 2018, except as noted in Note 21.
- (6) There were no restrictions placed on the Company's surplus, including for whom the surplus is being held.
- (7) The Company had no advances to surplus not repaid.
- (8) The Company did not hold any stock for any special purposes at December 31, 2019 or 2018.
- (9) Changes in the balances of special surplus funds from the prior year are due to the accrual of estimated ACA health insurer fees reclassified from unassigned funds or surplus to aggregate write-ins for special surplus funds as discussed more fully in Note 1.C and Note 22.
- (10) At December 31, 2019 and 2018, there were no unassigned funds that was represented or reduced by unrealized gains and losses
- (11) The Company has not issued any surplus notes or debentures or similar obligations at December 31, 2019 or 2018.
- (12) The Company did not participate in any quasi-reorganizations during the statement year.
- (13) The Company did not participate in any quasi-reorganizations in the past 10 years.

14. Liabilities, Contingencies and Assessments

A. The Company did not have any contingent commitments at December 31, 2019 or 2018.

B. Assessments

Guaranty Fund Assessments

(1) Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers as well as health insurers. The Company's assessments generally are based on a formula relating to the Company's health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payers such as not-for-profit consumer-governed health plans established under the ACA.

The Company did not have any contingent assessments at December 31, 2019 or 2018.

- C. The Company did not have any gain contingencies at December 31, 2019 or 2018.
- D. The Company did not have any claims related extra contractual obligation and bad faith losses stemming from lawsuits at December 31, 2019 or 2018.
- E. The Company did not have any joint and several liability arrangements at December 31, 2019 or 2018.
- F. Various liabilities arise in the normal course of the Company's business and have been recorded. In the opinion of management, any ultimate contingent losses will not have a material adverse effect on the Company's future results of operations and financial position. The Company, to the best of its knowledge, has no assets that it considers impaired that are not already recorded in the Company's books.

The Company maintains insurance coverage for certain litigation exposures in an amount it believes is reasonable.

NOTES TO FINANCIAL STATEMENTS

15. Leases

The Company did not have any material lease obligations at December 31, 2019 or 2018.

16. <u>Information about Financial Instruments with Off-Balance Sheet Risk and Financial Instruments with Concentrations of Credit</u>
Risk

The Company did not have any financial instruments with off-balance sheet risk or financial instruments with concentrations of credit risk at December 31, 2019 or 2018.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

The Company did not have any transfers of receivables reported as sales for the years ending December 31, 2019 or 2018.

B. Transfer and Servicing of Financial Assets

- (1) The Company did not have any loaned securities at December 31, 2019 or 2018.
- (2) and (3)

The Company did not have any servicing assets or liabilities at December 31, 2019 or 2018.

- (4) The Company did not have any securitized financial assets at December 31, 2019 or 2018.
- (5) The Company did not have any transfers of financial assets accounted for as secured borrowing at December 31, 2019 or 2018.
- (6) The Company did not have any transfers of receivables with recourse at December 31, 2019 or 2018.
- (7) The Company did not have any dollar repurchase or reverse repurchase agreements at December 31, 2019 or 2018.

C. Wash Sales

- (1) In the course of the Company's asset management, securities are sold and reacquired within 30 days of the sale date to enhance the Company's yield on its investment portfolio.
- (2) The Company had no securities sold during the year for the year ended December 31, 2019 and reacquired within 30 days of the sale date.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

- A. The Company did not serve as an Administrative Services Only plan administrator for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2019.
- B. The Company did not serve as an Administrative Services Contract (ASC) plan administrator for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2019.
- C. The Company did not have any Medicare or other similarly structured cost based reimbursement contracts for the period ended December 31, 2019.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

The Company did not have any material direct premiums written through/produced by managing general agents or third party administrators for the years ended December 31, 2019 and 2018.

20. Fair Value Measurements

A. and B.

Certain of the Company's financial instruments are measured at fair value in the financial statements. The fair values of these instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy. The following are the levels of the hierarchy and a brief description of the type of valuation information ("inputs") that qualifies a financial asset or liability for each level:

Level 1 – Unadjusted quoted prices for identical assets or liabilities in active markets.

NOTES TO FINANCIAL STATEMENTS

- Level 2 Inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, inputs that are observable that are not prices (such as interest rates and credit risks) and inputs that are derived from or corroborated by observable markets.
- Level 3 Developed from unobservable data, reflecting the Company's own assumptions.

Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation. When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classifies these assets and liabilities as Level 1. In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model. These financial assets and liabilities would then be classified as Level 2. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.

The valuation methods and assumptions used by the Company in estimating the fair value of debt securities are discussed in Note 1.

There were no material realized and unrealized capital gains, purchases, sales, settlements, or transfers into or out of the Company's Level 3 financial assets during 2019 or 2018.

C. The carrying values and estimated fair values of the Company's financial instruments at December 31, 2019 and 2018 were as follows:

December 31, 2019

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds, Short Term, and Cash Equivalents	\$133,405,882	\$131,630,202	\$ 55,800,364	\$ 77,605,518	s –	s —	\$ —

December 31, 2018

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds, Short Term, and Cash Equivalents	\$120,937,555	\$121,634,429	\$ 45,590,340	\$ 75,247,215	\$ —	\$ —	\$ —

The Company had no material assets and liabilities that are measured and reported at fair value as of December 31, 2019 and 2018.

In evaluating the Company's management of interest rate and liquidity risk and currency exposures, the fair values of all assets and liabilities should be taken into consideration, not only those presented above.

- D. The Company did not have any financial instruments where it was not practicable to estimate the fair value.
- E. The Company has not elected to use the net asset value practical expedient to fair value to measure its investments.

21. Other Items

The Company did not have any unusual or infrequent items for the years ended December 31, 2019 and 2018.

B. Troubled Debt Restructuring

The Company did not have any troubled debt restructuring in the years ended December 31, 2019 and 2018.

C. Other Disclosures

Minimum Capital and Surplus

Under the laws of the State of New Jersey, the Company is required to maintain a minimum capital and surplus equal to the greater of (1) \$1,000,000 adjusted annually by the Consumer Price Index; (2) 2% of the annual premium revenues as reported by the Company on its most recent annual financial statement filed with the Commissioner of Health and Commissioner of Banking and Insurance for the first \$150,000,000 of premium reported and 1% of the annual premium in excess of the first \$150,000,000 of premium reported; (3) an amount equal to the sum of three months of uncovered health care expenditures; or (4) an amount equal to the sum of 8% of the annual health care expenditures (not including those expenditures paid on a capitated basis and those made on a managed hospital payment basis) plus 4% of the annual hospital expenditures paid on a

NOTES TO FINANCIAL STATEMENTS

managed hospital payment basis. December 31, 2019 and 2018, the Company's capital and surplus exceeded all such requirements.

The NAIC utilizes risk-based capital ("RBC") standards for health organizations, including HMOs, that are designed to identify weakly capitalized companies by comparing each company's adjusted capital and surplus to its required capital and surplus (the "RBC Ratio"). The RBC Ratio is designed to reflect the risk profile of the company. Within certain ratio ranges, regulators have increasing authority to take action as the RBC Ratio decreases. There are four levels of regulatory action, ranging from requiring insurers to submit a comprehensive plan to the state insurance commissioner to requiring the state insurance commissioner to place the insurer under regulatory control. At December 31, 2019 and 2018, the Company had capital and surplus that exceeded the highest threshold specified by the RBC rules.

Health Care Reform

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, the "ACA"), made broad-based changes to the United States health care system. While the Company anticipates continued efforts in 2020 and beyond to invalidate, modify, repeal or replace the ACA, the Company expects aspects of the ACA to continue to significantly impact the Company's business operations and financial results, including pricing, medical benefit ratios ("MBRs") and the geographies in which the Company's products are available.

While most of the significant aspects of the ACA became effective during or prior to 2014, parts of the ACA continue to evolve through the promulgation of executive orders, legislation, regulations and guidance as well as ongoing litigation. Additional changes to the ACA and those regulations and guidance at the federal and/or state level are likely, and those changes are likely to be significant. Growing federal and state budgetary pressures make it more likely that any changes, including changes at the state level in response to changes to, or invalidation, repeal or replacement of, the ACA and/or changes in the funding levels and/or payment mechanisms of federally supported benefit programs, will be adverse to the Company. For example, if any elements of the ACA are invalidated or repealed at the federal level, the Company expects that some states would seek to enact similar requirements, such as prohibiting pre-existing condition exclusions, prohibiting rescission of insurance coverage, requiring coverage for dependents up to age 26, requiring guaranteed renewability of insurance coverage and prohibiting lifetime limits on insurance coverage.

Potential repeal of the ACA, ongoing legislative, regulatory and administrative policy changes to the ACA, the results of federal and state level elections, pending litigation challenging the constitutionality of the ACA or funding for the law and federal budget negotiations continue to create uncertainty about the ultimate impact of the ACA. The time frame for conclusion and final outcome and ultimate impact of this litigation are uncertain. Given the inherent difficulty of foreseeing the nature and scope of future changes to the ACA and how states, businesses and individuals will respond to those changes, the Company cannot predict the impact on it of future changes to the ACA. It is reasonably possible that invalidation, repeal or replacement of or other changes to the ACA and/or states' responses to such changes, in the aggregate, could have a significant adverse effect on the Company's businesses, results of operations and cash flows.

Medicaid

The Company's Medicaid, dual eligible and dual eligible special needs plan products also are heavily regulated by CMS and state Medicaid agencies, which have the right to audit the Company's performance to determine compliance with CMS contracts and regulations. The Company's Medicaid products, dual eligible products and Children's Health Insurance Program ("CHIP") contracts also are subject to complex federal and state regulations and oversight by state Medicaid agencies regarding the services the Company provides to Medicaid enrollees, payment for those services, network requirements (including mandatory inclusion of specified high-cost providers), and other aspects of these programs, and by external review organizations which audit Medicaid plans on behalf of the state Medicaid agencies. The laws, regulations and contractual requirements applicable to the Company and other participants in Medicaid and dual eligible programs, including requirements that the Company submit encounter data to the applicable state agency, are extensive, complex and subject to change. The Company has invested significant resources to comply with these standards, and its Medicaid and dual eligible program compliance efforts will continue to require significant resources. CMS and/or state Medicaid agencies may fine the Company, withhold payments to the Company, seek premium and other refunds, terminate the Company's existing contracts, elect not to award the Company new contracts or not to renew the Company's existing contracts, prohibit the Company from continuing to market and/or enroll members in or refuse to automatically assign members to one or more of the Company's Medicaid or dual eligible products, exclude the Company from participating in one or more Medicaid or dual eligible programs and/or institute other sanctions and/or civil monetary penalties against the Company if it fails to comply with CMS or state regulations or the Company's contractual requirements. The Company cannot predict whether pending or future federal or state legislation or court proceedings will change various aspects of the Medicaid program, nor can it predict the impact those changes will have on its business operations or financial results, but the effects could be materially adverse.

- D. The Company did not have any business interruption insurance recoveries for the years ending December 31, 2019 or 2018.
- E. The Company did not have any state transferable and non-transferable tax credits for the years ending December 31, 2019 or 2018.
- F. The Company did not have any subprime mortgage related risk exposures at December 31, 2019 or 2018.
- G. The Company did not have any retained assets at December 31, 2019 or 2018.
- H. The Company did not have any insurance-linked securities ("ILS") contracts at December 31, 2019 or 2018.
- I. The Company did not have amounts that could be realized on life insurance at December 31, 2019 or 2018.

NOTES TO FINANCIAL STATEMENTS

22. Events Subsequent

Type I - Recognized Subsequent Events

Subsequent events have been considered through February 28, 2020 for the statutory statement issued on February 28, 2020.

The Company had no known reportable recognized subsequent events.

Type II - Nonrecognized Subsequent Events

Subsequent events have been considered through February 28, 2020 for the statutory statement issued on February 28, 2020.

In January 2020, the Company was informed by the New Jersey Department of Human Services ("NJDHS") that NJDHS was going to reduce the Company's medical loss ratio ("MLR") rebate liability by approximately \$11.2 million pursuant to a revised MLR rebate calculation.

On January 1, 2020, the Company will be subject to an annual fee under Section 9010 of the Federal Affordable Care Act ("ACA"). This annual fee will be allocated to individual health insurers based on the ratio of the amount of the entity's net premiums written during the preceding calendar year to the amount of health insurance for any U.S. health risk that is written during the preceding calendar year. A health insurance entity's portion of the annual fee becomes payable once the entity provides health insurance for any U.S. health risk for each calendar year beginning on or after January 1 of the year the fee is due. As of December 31, 2019, the Company has written health insurance subject to the ACA assessment, expects to conduct health insurance business in 2020, and estimates its portion of the annual health insurance industry fee to be payable on September 30, 2020 to be \$5,271,400. This amount is reflected in special surplus. This assessment is expected to impact risk based capital ("RBC") by 8%. Reporting the ACA assessment as of December 31, 2019, would not have triggered an RBC action level.

On January 22, 2018, Public Law No: 115-120 was signed into law and it imposes a moratorium on the health insurer fee for calendar year 2019. As a result, there was no annual health insurance industry fee payable on September 30, 2019 and there were no amounts reflected in the Company's aggregate write-ins for special surplus funds related to this payable at December 31, 2018. There was also no resulting impact to the Company's RBC to assess as of December 31, 2018 as a result of this suspension.

			(Current Year	Prior Year
A.	Did the reporting entity write accident and health insurance premium that is subject to Section 9010 of the Federal Affordable Care Act (YES/NO)?	Yes			
В.	ACA fee assessment payable for the upcoming year		\$	5,271,400	\$ _
C.	ACA fee assessment paid			_	\$ 2,848,039
D.	Premium written subject to ACA 9010 assessment		\$	261,718,496	_
E.	Total Adjusted Capital before surplus adjustment		\$	64,755,115	
	(Five-Year Historical Line 14)				
F.	Total Adjusted Capital after surplus adjustment (Five-Year Historical Line 14 minus 22B above)		\$	59,483,715	
G.	Authorized Control Level (Five-Year Historical Line 15)		\$	16,691,954	
Н.	Would reporting the ACA assessment as of Dec. 31, 2019 have triggered an RBC action level (YES/NO)?	No			

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 – General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?

Yes() No(X)

If yes, give full details. N/A

NOTES TO FINANCIAL STATEMENTS

(2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes() No(X)

If yes, give full details. N/A

Section 2 – Ceded Reinsurance Report – Part A

(1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than nonpayment of premium or other similar credit?

Yes() No (X)

- a. If yes, what is the estimated amount of the aggregate reduction in surplus of a unilateral cancellation by the reinsurer as of the date of this statement, for those agreements in which cancellation results in a net obligation of the reporting entity to the reinsurer, and for which such obligation is not presently accrued? Where necessary, the reporting entity may consider the current or anticipated experience of the business reinsured in making this estimate. N/A.
- b. What is the total amount of reinsurance credits taken, whether as an asset or as a reduction of liability for these agreements in this statement? N/A.
- (2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes() No (X)

If yes, give full details. N/A

Section 3 – Ceded Reinsurance Report – Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the insurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate. N/A.
- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement?

Yes() No(X)

If yes, what is the amount of reinsurance credit, whether an asset or a reduction of liability, taken for such new agreements or amendments? N/A.

- B. The Company did not have uncollectible reinsurance at December 31, 2019 or 2018.
- C. The Company did not have any commutation of ceded reinsurance at December 31, 2019 or 2018.
- D. The Company's certified reinsurer's rating has not been downgraded or its status subject to revocation at December 31, 2019 or 2018.
- 24. Retrospectively Rated Contracts and Contracts Subject to Redetermination

A. and B.

The Company did not have any retrospectively rated contracts in 2019 or 2018.

C. Contracts Subject to Retrospective Rating Features

The Company did not have any contracts subject to retrospective rating features in 2019 or 2018.

D. Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act

The Company did not have any medical loss ratio rebates required pursuant to the Public Health Service Act in 2019 or 2018.

NOTES TO FINANCIAL STATEMENTS

E. Risk Sharing Provisions of the Affordable Care Act (ACA)

- (1) Did the reporting entity write accident and health insurance premium which is subject to the ACA risk sharing provisions (YES/NO)? Yes $[\]$ No [X]
- (2) through (5): Not applicable.

25. Change in Incurred Claims and Claims Adjustment Expense

The following table shows the components of the change in claims unpaid, unpaid claims adjustment expense and aggregate health claim reserves for the years ended December 31, 2019 and 2018.

	 2019	2018
Balance, January 1	\$ 49,719,727 \$	37,624,994
Health care receivable	\$ (2,730,878) \$	(1,593,261)
Balance, January 1, net of health care receivable	\$ 46,988,849 \$	36,031,733
Incurred related to:		
Current year	\$ 424,473,287 \$	332,318,733
Prior years	\$ (3,591,688) \$	(7,512,693)
Total incurred	\$ 420,881,599 \$	324,806,040
Paid related to:		
Current year	\$ 368,494,613 \$	284,305,038
Prior years	\$ 41,542,648 \$	29,543,886
Total paid	\$ 410,037,261 \$	313,848,924
Balance, December 31, net of health care receivable	\$ 57,833,187 \$	46,988,849
Health care receivable	\$ 1,942,744 \$	2,730,878
Balance, December 31	\$ 59,775,931 \$	49,719,727

- A. Reserves as of December 31, 2018 were \$49,719,726. As of December 31, 2019, \$41,542,648 has been paid for incurred claims and claim adjustment expenses attributable to insured events of prior years. Reserves remaining for prior years are now \$4,585,390 as a result of re-estimation of unpaid claims and claim adjustment expenses. Therefore, there has been a \$3,591,688 favorable prior-year development since December 31, 2018 to December 31, 2019. The decrease is generally the result of ongoing analysis of recent loss development trends. Original estimates are increased or decreased, as additional information becomes known regarding individual claims.
- B. There has been no significant change in the Company's methodologies and assumptions used in calculating the liability for unpaid claims and claim adjustment expenses.

26. Intercompany Pooling Arrangements

The Company did not have any intercompany pooling arrangements at December 31, 2019 or 2018.

27. Structured Settlements

The Company did not have any structured settlements at December 31, 2019 or 2018.

28. <u>Health Care Receivables</u>

A. Pharmaceutical Rebate Receivables

The Company receives pharmaceutical rebates from AHM pursuant to the plan joinder agreement between the Company, AMA and AHM discussed in Note 10. AHM has contracted with Caremark, an affiliate, to deliver pharmacy benefit management services to the Company. The Company receives rebates from AHM that relate to the Company's membership. The Company estimates pharmaceutical rebate receivables based upon the historical payment trends, actual utilization and other variables. Actual rebates collected are applied to the collection periods below, using a first in first out methodology. At

NOTES TO FINANCIAL STATEMENTS

December 31, 2019 there were no and in 2018, the Company had pharmaceutical rebate receivables of \$316,510, respectively (refer to the Company's accounting practices related to pharmaceutical rebate receivables in Note 1).

The following table discloses the quarterly revenue and subsequent cash collections relating to the pharmaceutical rebates discussed in Note 10.

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing		Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2019	\$ 424,963	\$ 424,963	\$ 424,963	1	\$ —	\$
09/30/2019	\$ 462,056	\$ 424,963	\$ 424,963		_	_
06/30/2019	\$ 415,424	\$ 461,954	\$ 140,727		\$ 321,227	_
03/30/2019	\$ 289,632	\$ 444,517	\$ 150,444		\$ 238,345	\$ 55,728
12/31/2018	\$ 316,510	\$ 356,387	\$ 149,282		\$ 202,447	\$ 4,658
09/30/2018	\$ 280,100.00	\$ 316,352	\$ 112,509		\$ 191,135	\$ 12,708
06/30/2018	\$ 304,015.00	\$ 279,926	\$ 63,043		\$ 213,488	\$ 3,395
03/31/2018	\$ 246,438.00	\$ 222,863	\$ 76,508		\$ 144,688	\$ 1,667
12/31/2017	\$ 188,265.00	\$ 245,005	\$ 89,518		\$ 155,458	\$ 29
09/30/2017	\$ 167,256.00	\$ 187,192	\$ 98,744		\$ 87,118	\$ 1,330
06/30/2017	\$ 123,402.00	\$ 166,151	\$ 56,431		\$ 107,384	\$ 2,336
03/31/2017	\$ 121,508.00	\$ 123,471	\$ 41,655		\$ 78,683	\$ 3,133

¹ Represents a portion of the estimated rebates for the quarter ending December 31, 2019, which were paid by AHM to the Company prior to December 31, 2019 and invoicing in 2020.

B. Risk sharing receivables

The Company did not have any admitted risk sharing receivables at December 31, 2019 or 2018.

29. Participating Policies

The Company did not have any participating policies at December 31, 2019 or 2018.

30. Premium Deficiency Reserves

December 31, 2019

1. Liability carried for premium deficiency reserves

\$---

2. Date of the most recent evaluation of this liability

12/31/2019

 ${\it 3.}\ \ Was\ anticipated\ investment\ income\ utilized\ in\ the\ calculation?$

No

31. Anticipated Salvage and Subrogation

The Company did not reduce its liability for unpaid claims/losses by any estimated anticipated salvage and subrogation at December 31, 2019 or 2018 as the Company records salvage and subrogation on a paid basis when cash is received.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System is an insurer? If yes, complete Schedule Y, Parts 1, 1A and 2		X] No []	
1.2	If yes, did the reporting entity register and file with its domiciliary State Insur such regulatory official of the state of domicile of the principal insurer in the providing disclosure substantially similar to the standards adopted by the Naits Model Insurance Holding Company System Regulatory Act and model resubject to standards and disclosure requirements substantially similar to the	Holding Company System, a registration statement ational Association of Insurance Commissioners (NAIC) in equilations pertaining thereto, or is the reporting entity	[X] No [] N/A []
1.3	State Regulating?	New J	ersey	
1.4	Is the reporting entity publicly traded or a member of a publicly traded group	9?	Yes [)	X] No []
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issue	ed by the SEC for the entity/group	00000	64803
2.1	Has any change been made during the year of this statement in the charter reporting entity?		Yes [] No [X]
2.2	If yes, date of change:			
3.1	State as of what date the latest financial examination of the reporting entity	was made or is being made.	12/31,	/2015
3.2	State the as of date that the latest financial examination report became ava entity. This date should be the date of the examined balance sheet and not		12/31	/2015
3.3	State as of what date the latest financial examination report became available domicile or the reporting entity. This is the release date or completion date of examination (balance sheet date).	of the examination report and not the date of the	06/26	/2017
3.4	By what department or departments? New Jersey Department of Banking and Insurance			
3.5	Have all financial statement adjustments within the latest financial examinal statement filed with Departments?		[] No [] N/A [X]
3.6	Have all of the recommendations within the latest financial examination rep	ort been complied with? Yes	[] No [] N/A [X]
4.1	4.12 renewals During the period covered by this statement, did any sales/service organiza	of the reporting entity), receive credit or commissions for or contro sured on direct premiums) of: new business?? ition owned in whole or in part by the reporting entity or an affiliate	Yes [Yes [] No [X]] No [X]
	receive credit or commissions for or control a substantial part (more than 20 premiums) of:	percent or any major line or business measured on direct	Voo. I	1 No [V 1
		?] No [X]] No [X]
5.1	Has the reporting entity been a party to a merger or consolidation during the If yes, complete and file the merger history data file with the NAIC.	e period covered by this statement?	Yes [] No [X]
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of do ceased to exist as a result of the merger or consolidation.	omicile (use two letter state abbreviation) for any entity that has		
	1 Name of Entity	2 3 NAIC Company Code State of Domicile		
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrarevoked by any governmental entity during the reporting period?] No [X]
6.2	If yes, give full information:			
7.1	Does any foreign (non-United States) person or entity directly or indirectly or	ontrol 10% or more of the reporting entity?	Yes [] No [X]
7.2	If yes, 7.21 State the percentage of foreign control; 7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the enti- attorney-in-fact; and identify the type of entity(s) (e.g., individual, corpo	ty is a mutual or reciprocal, the nationality of its manager or or or government, manager or attorney in fact).	<u>.</u>	0.0 %
	1 Nationality	2 Type of Entity		
			1	

8.1 8.2]	No [Х]
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities firms?]	No [Х]
	1 Affiliate Name	` ' ' '	3 4 FRB OCC	5 FDIC	6 SEC	_		
9.	What is the name and address of the independent certified public acc Ernst & Young LLP; 200 Clarendon Street; Boston, MA 02116	countant or accounting firm retained to conduct the an	nual audit?			_		
10.1	Has the insurer been granted any exemptions to the prohibited non-al requirements as allowed in Section 7H of the Annual Financial Reportation regulation?	ting Model Regulation (Model Audit Rule), or substant	tially similar stat	te	Yes []	No [Х]
10.2	If the response to 10.1 is yes, provide information related to this exem							
10.3 10.4	allowed for in Section 18A of the Model Regulation, or substantially similar state law or regulation?						No [Х]
10.5 10.6	Has the reporting entity established an Audit Committee in compliance of the response to 10.5 is no or n/a, please explain	e with the domiciliary state insurance laws?	Υι	es [X]	No []	N/A	[]
11.	What is the name, address and affiliation (officer/employee of the rep firm) of the individual providing the statement of actuarial opinion/cert Katie Lau, A.S.A., M.A.A.A.; 151 Farmington Avenue; Hartford, CT 06	ification?	actuarial consul	ting				
12.1	Does the reporting entity own any securities of a real estate holding or	ompany or otherwise hold real estate indirectly?			Yes []	No [Χ]
		estate holding company			_			
		arcels involved						
12.2	If, yes provide explanation:	ljusted carrying value						0
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTIT	TES ONI Y						
13.1	What changes have been made during the year in the United States IN/A	manager or the United States trustees of the reporting	•					
13.2	Does this statement contain all business transacted for the reporting of	entity through its United States Branch on risks where	ver located?		Yes []	No []
13.3	Have there been any changes made to any of the trust indentures dur	9			Yes []	No []
13.4	If answer to (13.3) is yes, has the domiciliary or entry state approved to				No []	N/A	[]
14.1	Are the senior officers (principal executive officer, principal financial o similar functions) of the reporting entity subject to a code of ethics, what a. Honest and ethical conduct, including the ethical handling of actual relationships;	nich includes the following standards?or apparent conflicts of interest between personal an	d professional		Yes [X]	No []
	 b. Full, fair, accurate, timely and understandable disclosure in the per c. Compliance with applicable governmental laws, rules and regulatio 		Γ;					
	d. The prompt internal reporting of violations to an appropriate person							
14.11	e. Accountability for adherence to the code.							
440					v . r v	,		,
	Has the code of ethics for senior managers been amended?				Yes [X	J	NO [J
	Added a statement at the end of the Privacy and Security of Personal Added additional examples of what may present an actual or potentia sale, exchange of alcohol on CVS premises, or at any time when repr approved business meal or legitimate business event. Updated conte policy and procedure governing MG&E. Clarified that antitrust laws a Added that our Medicare FWA program also includes processes to mexample of FWA activities to include reviewing for abnormal Part C p	Information indicating that international privacy laws in conflict of interest. Clarified that the unauthorized us esenting CVS is strictly prohibited except when associant related to Meals, Gifts, and Entertainment to align the designed to protect competition by prohibiting monula mage identified issues through corrective actions. As	se, possession, siated with an with the latest opolization as w dded additional	vell.				
14.3	Have any provisions of the code of ethics been waived for any of the				Yes []	No [Х]
14.31	If the response to 14.3 is yes, provide the nature of any waiver(s).							

15.1	15.1 Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List?						1 1	No [X	1
15.2	If the response t	o 15.1 is yes, indicate the American Bankers Association (ABA) Rer of Credit and describe the circumstances in which the Letter of C	outing Number	and the name of the issuing or confirm	ning	.00 [•
	1 American Bankers Association	2		3			4		
	(ABA) Routing Number	Issuing or Confirming Bank Name		That Can Trigger the Letter of Credit			nount		
									===
16.	Is the purchase	BOARD OF D or sale of all investments of the reporting entity passed upon either	_						
17.	thereof?	ng entity keep a complete permanent record of the proceedings of				Yes [X	-]
18.	Has the reporting	g entity an established procedure for disclosure to its board of dire	ctors or trustee	s of any material interest or affiliation of	n the	Yes [X]
	part of any of its	officers, directors, trustees or responsible employees that is in cor	iffict with the or	ticial duties of such person?		TES [A	,] r	NO [J
10	11	FINAN		Section (see Occupil) Accepted					
19.		ent been prepared using a basis of accounting other than Statutory ciples)?				Yes [] [No [X]
20.1		aned during the year (inclusive of Separate Accounts, exclusive of		20.11 To directors or other officers		.\$			0
				20.12 To stockholders not officers		.\$			0
				20.13 Trustees, supreme or grand (Fraternal Only)		•			٥
20.2	Total amount of	loans outstanding at the end of year (inclusive of Separate Accour	nte evolucive o			\$			0
20.2	policy loans):	loans outstanding at the end of year (inclusive of Separate Accour	its, exclusive of	20.21 To directors or other officers		.\$			0
	, , , , , ,			20.22 To stockholders not officers					
				20.23 Trustees, supreme or grand					
				(Fraternal Only)		\$			0
21.1	Were any assets	s reported in this statement subject to a contractual obligation to tra reported in the statement?	ansfer to anothe	er party without the liability for such		l seV	1 1	No L A	1
21.2		amount thereof at December 31 of the current year:		21.21 Rented from others					
	,00, 0.0.0	amount and sor at 2000mast of or and barronk your.		21.22 Borrowed from others					
				21.23 Leased from others					
				21.24 Other					
22.1	Does this statem	nent include payments for assessments as described in the Annua ation assessments?	Statement Ins	tructions other than quaranty fund or					
22.2	If answer is yes:			2.21 Amount paid as losses or risk adju					
				2.22 Amount paid as expenses					
				2.23 Other amounts paid					
23.1 23.2		ng entity report any amounts due from parent, subsidiaries or affilia ny amounts receivable from parent included in the Page 2 amount							
		INVEST.							
24.04	\\\	INVESTI							
24.01		cks, bonds and other securities owned December 31 of current years of the reporting entity on said date? (other than securities le				Yes [)	(] 1	No []
24.02	. •	nd complete information relating thereto							
24.03	whether collater	ding programs, provide a description of the program including value al is carried on or off-balance sheet. (an alternative is to reference	Note 17 where	this information is also provided)					
24.04		any's security lending program meet the requirements for a conform			Yes [] No []	N/A [Х]
24.05	If answer to 24.0	14 is yes, report amount of collateral for conforming programs				\$			0
24.06	If answer to 24.0	04 is no, report amount of collateral for other programs.				\$			0
	outset of the cor	rities lending program require 102% (domestic securities) and 105° htract?							
24.08	Does the reporti	ng entity non-admit when the collateral received from the counterp	arty falls below	100%?	Yes [] No []	N/A [Х]
24.09		ng entity or the reporting entity 's securities lending agent utilize thes lending?			Yes [] No []	N/A [Х]

24.10	For the reporting entity's security lending program state the amount	ount of the following as December 31 of the current year:				
	24.101 Total fair value of reinvested collateral a	\$			0	
	24.102 Total book adjusted/carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2					0
	24.103 Total payable for securities lending repo	.\$			0	
25.1	Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under the control of the reporting entity, or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in force? (Exclude securities subject to Interrogatory 21.1 and 24.03).					
25.2	If yes, state the amount thereof at December 31 of the current y	ear: 25.21 Subject to repurchase agreements	\$			0
	in you, state the amount the source at 2000 mass, or at the carrointy	25.22 Subject to reverse repurchase agreements				
		25.23 Subject to dollar repurchase agreements				
		25.24 Subject to reverse dollar repurchase agreements				
		25.25 Placed under option agreements	\$			0
		25.26 Letter stock or securities restricted as to sale - excluding FHLB Capital Stock	\$			0
		25.27 FHLB Capital Stock	\$			0
		25.28 On deposit with states	\$		52,04	47,754
		25.29 On deposit with other regulatory bodies	\$			0
		25.30 Pledged as collateral - excluding collateral pledged an FHLB	(O			0
		25.31 Piedged as collateral to FHLB - including assets backing funding agreements	s			0
		25.32 Other	\$			0
25.3	For category (25.26) provide the following:					
	1 Nature of Restriction	2 Description	Ar	3 noun	ıt	
26.1 26.2		d on Schedule DB? Yes [
LINES 2	6.3 through 26.5: FOR LIFE/FRATERNAL REPORTING ENTITI	ES ONLY:				
26.3	Does the reporting entity utilize derivatives to hedge variable an	nuity guarantees subject to fluctuations as a result of interest rate sensitivity?	Yes []	No [Х]
26.4	If the response to 26.3 is YES, does the reporting entity utilize:					
		3.41 Special accounting provision of SSAP No. 108		_	No []
		.42 Permitted accounting practice	_	J l	_	J 1
			163 [1	NO [1
26.5	following:	unting provisions of SSAP No. 108, the reporting entity attests to the	Yes []	No []
	reserves and provides the impact of the hedging strate. • Financial Officer Certification has been obtained which	•				
27.1	.1 Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity?					Х]
27.2	.2 If yes, state the amount thereof at December 31 of the current year.					0
28.	offices, vaults or safety deposit boxes, were all stocks, bonds ar custodial agreement with a qualified bank or trust company in a	estate, mortgage loans and investments held physically in the reporting entity's nd other securities, owned throughout the current year held pursuant to a ccordance with Section 1, III - General Examination Considerations, F. eements of the NAIC Financial Condition Examiners Handbook?	Yes [Х]	No []
28.01	For agreements that comply with the requirements of the NAIC	Financial Condition Examiners Handbook, complete the following:				
	1	2				1
	Name of Custodian(s)	Custodian's Address ate Street Financial Center; One Lincoln Street; Boston, MA 02111-2900]
	State Street Bank and Trust Company	te Street Financial Center; One Lincoln Street; Boston, MA 02111-2900				

N	1 ame(s)	2 Locatio	` '	3 Complete Explanat		
Have there been any cha If yes, give full and comp	-	nanges, in the custodian(s) identifienthereto:	d in 28.01 during the current ye	ear?	Yes []] No [
1 Old Cus	todian	2 New Custodian	3 Date of Change	4 Reaso	on	
make investment decision	ns on behalf of the repor	advisors, investment managers, b ting entity. For assets that are mar ounts"; "handle securities"]	naged internally by employees o			
Kevin J. Casey as Seni	1 Name of Firm or Individer Dr Investment Officer		ffiliation			
		able for Question 28.05, do any firm n 10% of the reporting entity's inve			Yes [] No [
		reporting entity (i.e. designated wit te to more than 50% of the reporting			Yes [] No [
For those firms or individe the table below.	uals listed in the table for	r 28.05 with an affiliation code of "A	\" (affiliated) or "U" (unaffiliated), provide the information for	r	
1		2	3	4	Mar	5 estme nagem
Central Registration Depository Number Ke		f Firm or Individual	Legal Entity Identifier (LE	/ 	ı (IÑ	reeme IA) File
	have any diversified mut SEC) in the Investment (tual funds reported in Schedule D, Company Act of 1940 [Section 5(b)	Part 2 (diversified according to		•	
1		2			3 Book/Adjus	
29.2999 - Total		Name of Mut	ual Fund		Carrying Va	alue 0
For each mutual fund list	ed in the table above, co	mplete the following schedule:		,		
	1		2	3	4	ļ
			<u>-</u>	Amount of Mutua Fund's Book/Adjus Carrying Value	sted	

30.	Provide the following information for all short-term and long-term bonds and all preferred stocks.	Do not substitute amortized value or
	statement value for fair value.	

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
30.1 Bonds	131,629,121	133,404,801	1,775,680
30.2 Preferred stocks	0	0	0
30.3 Totals	131,629,121	133,404,801	1,775,680

30.4	Describe the sources or methods utilized in determining the fair values:				
	Fair value of long term bonds and preferred stocks are determined based on quoted market prices when available, fair values using valuation methodologies based on available and observable market information, or by using matrix pricing. If quoted market prices are not available, we determine fair value using broker quoted or an internal analysis of each investment's financial performance and cash flow projections. Short-term investments are carried at amortized cost which approximated fair value. The carrying value of cash equivalents approximated fair value.				
31.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes [. 1	No [Х]
31.2	If the answer to 31.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes	. 1	No []
31.3	If the answer to 31.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:				
	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Yes	Х]	No []
33.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments.				
	c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal. Has the reporting entity self-designated 5GI securities?	Yes [i 1	No [X 1
34.	By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.		•		
	Has the reporting entity self-designated PLGI securities?	Yes [. 1	No [Х]
35.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?	Yes	[]	No [Х]
	OTHER				
36.1	Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?	\$			(
36.2	List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade association service organizations and statistical or rating bureaus during the period covered by this statement.	3,			
	1 2				
	Name Amount Paid				

37.1	Amount of payments for legal expenses, if any?			0
37.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment during the period covered by this statement.	nents for legal expenses	5	
	1 Name	2 Amount Paid		
38.1	Amount of payments for expenditures in connection with matters before legislative bodies, officers or department	nents of government, if a	any?\$	0
38.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment connection with matters before legislative bodies, officers or departments of government during the period co			
	1 Name	2 Amount Paid		

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1	Does the reporting entity have any direct Medicare Supplement Insurance in force				
1.2	If yes, indicate premium earned on U.S. business only.				
1.3	What portion of Item (1.2) is not reported on the Medicare Supplement Insurance 1.31 Reason for excluding	Experience Exhibit?	.\$		
	1.31 Reason for excluding				
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Alien n	not included in Item (1.2) above	\$		0
1.5	Indicate total incurred claims on all Medicare Supplement Insurance.				
1.6	Individual policies:	Most current three years:			
		1.61 Total premium earned	.\$		0
		1.62 Total incurred claims	.\$		0
		1.63 Number of covered lives			0
		All years prior to most current three years:			
		1.64 Total premium earned	.\$		0
		1.65 Total incurred claims			
		1.66 Number of covered lives			0
4 7	One we will also	Mark assessed these second			
1.7	Group policies:	Most current three years:	Φ.		0
		1.71 Total premium earned			
		1.72 Total incurred claims			
		All years prior to most current three years:			
		1.74 Total premium earned			0
		1.75 Total incurred claims			
		1.76 Number of covered lives			
2.	Health Test:				
		1 2			
	O.A. Barriar N. marriar	Current Year Prior Year			
	2.1 Premium Numerator				
	2.2 Premium Denominator				
	2.3 Premium Ratio (2.1/2.2)2.4 Reserve Numerator	70,007,272 50,206,520			
	2.4 Reserve Numerator	70,007,373 59,306,320			
	2.6 Reserve Ratio (2.4/2.5)				
	2.0 1000170 1000 (2.112.0)				
3.1	Has the reporting entity received any endowment or gift from contracting hospitals returned when, as and if the earnings of the reporting entity permits?	s, physicians, dentists, or others that is agreed will be	Yes [] No [Х]
4.1	Have copies of all agreements stating the period and nature of hospitals', physicial dependents been filed with the appropriate regulatory agency?		Yes [X] No []
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these	e agreements include additional benefits offered?	Yes [] No [X]
5.1	Does the reporting entity have stop-loss reinsurance?		Yes [X] No [.]
5.2	If no, explain:				
5.3	Maximum retained risk (see instructions)	5.31 Comprehensive Medical	.\$		0
	,	5.32 Medical Only	\$	3	350,000
		5.33 Medicare Supplement	.\$		0
		5.34 Dental & Vision	.\$		0
		5.35 Other Limited Benefit Plan	\$		0
		5.36 Other	.\$		0
6.	Describe arrangement which the reporting entity may have to protect subscribers hold harmless provisions, conversion privileges with other carriers, agreements wagreements:	vith providers to continue rendering services, and any other			
	The Company assures that members are not liable for its debts if it becomes insc				
7.1	Does the reporting entity set up its claim liability for provider services on a service	e date basis?	Yes [X] No []
7.2	If no, give details				
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year.			.13,492
	5 5 51 Pro 51 11 11	8.2 Number of providers at end of reporting year			
		. •,			
9.1	Does the reporting entity have business subject to premium rate guarantees?		Yes [] No [X]
9.2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months.			
		9.22 Business with rate guarantees over 36 months	\$		0

10.1	Does the reporting entity have Incentive Pool, Withh	old or Bonus An	rangements in its p	rovider contracts?			Yes [X] No []
10.2	If yes:		10	0.21 Maximum am	ount payable boni	uses	\$	873,932
			10	0.22 Amount actua	lly paid for year b	onuses	\$	1,631,019
						holds		
			10	0.24 Amount actua	lly paid for year w	rithholds	\$	0
11.1	Is the reporting entity organized as:							
						del,] No [X]
						ociation (IPA), or, .	_] No [X]
				11.14 A Mixed	Model (combination	on of above)?	Yes [] No [X]
11 2	In the reporting entity authors to Statutory Minimum	Capital and Surn	lua Baguiramanta'				V l agV] No []
11.2 11.3	Is the reporting entity subject to Statutory Minimum of tyes, show the name of the state requiring such mi						_	New Jersey
11.4	If yes, show the amount required.							33,383,908
11.5	Is this amount included as part of a contingency rese							
11.6	If the amount is calculated, show the calculation							
	See Notes to Financial Statement - Note 21, Other I	tems, C., Other	Disclosures.					
12.	List service areas in which reporting entity is license	d to operate:						
			1					
	A414:-	Danier Divilie	Name of Service					
			ngton, Camden, Car erdon, Mercer, Mid					
		, ,	omerset, Sussex,		· · · · · · · · · · · · · · · · · · ·			
					<u> </u>			
13.1	Do you act as a custodian for health savings accour	nts?					Yes [] No [X]
13.2	If yes, please provide the amount of custodial funds	held as of the re	porting date				s	0
	yoo, prodoo provido are arribant or babilbanar tariab		pog aa.c				····•	
13.3	Do you act as an administrator for health savings ac	counts?					Yes [] No [X]
							_	
13.4	If yes, please provide the balance of funds administe	ered as of the rep	porting date				\$	0
14.1	Are any of the captive affiliates reported on Schedul		orized reinsurers?			Yes [] No [] N/A [X]
14.2	If the answer to 14.1 is yes, please provide the follow	wing:						
	1	2	3	4	Assets	s Supporting Reserv	e Credit	
	·	NAIC	· ·		5	6	7	
	O-many Norma	Company	Domiciliary	Reserve	Letters of	Trust	011	
	Company Name	Code	Jurisdiction	Credit	Credit	Agreements	Othe	
15.	Provide the following for individual ordinary life insur ceded):	ance* policies (l	J.S. business only	for the current ye	ar (prior to reinsur	ance assumed or		
	cedea).			15 1 Г	irect Premium W	ritten	\$	0
						ms		
						d Lives		
		*Ordir	nary Life Insurance	Includes				
	Term(whether full und							
	Whole Life (whether to Variable Life (with or			g, jet issue, "short	form app")			
	Universal Life (with or							
	Variable Universal Life			antee)				
								
16.	Is the reporting entity licensed or chartered, registered	ed, qualified, elig	ible or writing busi	ness in at least tw	o states?		Yes []	No [X]
16.1							Vac [1	No F V 1
	domicile of the reporting entity?						Yes []	No [X]

FIVE-YEAR HISTORICAL DATA

		1 2019	2 2018	3 2017	4 2016	5 2015
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	146,937,009	133,013,144	134,619,762	119,562,326	50,036,452
2.	Total liabilities (Page 3, Line 24)	82,181,894	80,123,801	98,332,149	84,228,578	37,745,951
3.	Statutory minimum capital and surplus requirement	33,383,908	26,573,350	22,409,014	9,038,188	7,321,166
4.	Total capital and surplus (Page 3, Line 33)	64,755,115	52,889,343	36,287,613	35,333,748	12,290,501
	Income Statement (Page 4)					
5.	Total revenues (Line 8)	459,347,324	374,461,307	233,756,302	137,983,073	68,389,594
6.	Total medical and hospital expenses (Line 18)	397,088,219	307,647,345	182,811,322	94,075,723	64,452,996
7.	Claims adjustment expenses (Line 20)	23,793,380	17, 158, 695	11,901,220	7,403,303	3,733,654
8.	Total administrative expenses (Line 21)	28,638,154	30,618,399	16,966,129	11,093,993	4,248,288
9.	Net underwriting gain (loss) (Line 24)	9,827,571	19,036,868	22,077,631	25,410,054	(4,045,344)
10.	Net investment gain (loss) (Line 27)			1,971,768	839,791	(78,585)
11.	Total other income (Lines 28 plus 29)				(459,999)	0
12.	Net income or (loss) (Line 32)				16,081,913	(2,635,425)
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	21,385,316	2,052,303	27,415,429	48,559,906	29,954,474
	Risk-Based Capital Analysis	, ,			, ,	
14.	Total adjusted capital	64.755.115	52.889.343	36.287.613	35.333.748	12.290.501
15.	Authorized control level risk-based capital					
	Enrollment (Exhibit 1)	, , , , ,	, ,	, ,	, , , ,	, , ,
16.	Total members at end of period (Column 5, Line 7)	65.834	58.386	45.655	33.335	18.578
17.	Total members months (Column 6, Line 7)					
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)			78.2	68.2	94.2
20.	Cost containment expenses					
21.	Other claims adjustment expenses					
22.	Total underwriting deductions (Line 23)					
23.	Total underwriting gain (loss) (Line 24)	2.1	5.1	9.4	18.4	(5.9)
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 13, Col. 5)	44,277,179	29,464,440	23,906,860	11,234,985	0
25.	Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]	45 , 137 , 989	35,383,872	30,162,313	34,521,118	0
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	L0 L	0	0
27.						
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)					
29.	•					
30.	Affiliated mortgage loans on real estate					0
31.	All other affiliated					0
32.	Total of above Lines 26 to 31				0	0
33.						
	31 above. If a party to a merger, have the two most recent years of	0	0	0	0	0

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories

1. A 2. A 3. Al 4. Al 5. C 6. C 7. C 8. D 9. D	Alaska	AL AK AZ AR CO CT DE DC FL GA	Active Status (a) N.	Accident & Health Premiums 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3 Medicare Title XVIII 0 0 0 0 0 0 0	Medicaid Title XIX 0 0 0 0	5 Federal Employees Health Benefits Plan Premiums	Life & Annuity Premiums & Other Considerations	7 Property/ Casualty Premiums	8 Total Columns 2 Through 7	9 Deposit-Type Contracts
1. A 2. A 3. Al 4. Al 5. C 6. C 7. C 8. D 9. D	Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii daho	AK AZ AR CA CO CT DE DC FL	Status (a)	Health	Title XVIII	Title XIX	Health Benefits Plan Premiums	Premiums & Other Considerations	Casualty Premiums	Columns 2 Through 7	
1. A 2. A 3. Al 4. Al 5. C 6. C 7. C 8. D 9. D	Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii daho	AK AZ AR CA CO CT DE DC FL	N.	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0							Contracts
2. A 3. A 4. A 5. C 6. C 7. C 8. D 9. D	Alaska Arizona Arkansas California Colorado Connecticut District of Columbia Florida Georgia Hawaii daho	AK AZ AR CA CO CT DE DC FL		0 0 0 0 0	0 0 0	0	n			1 0	0
4. Al 5. C 6. C 7. C 8. D 9. D	Arizona	AZ AR CA CO CT DE DC FL	N. N	0 0 0 0	0	0	U	0	0	0	0
5. C. 6. C. 7. C. 8. D. 9. D	California	CA CO CT DE DC FL	NNNNNNN	0 0	0 0		0	0	0	0	0
6. C 7. C 8. D 9. D	Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii daho	CO CT DE DC FL	N	0	0	L0	0	0	0	0	0
7. C 8. D 9. D	Connecticut Delaware District of Columbia Florida Georgia Hawaii Ulinois	CT DE DC FL	NNNN	0		0	0	0	0	0	0
8. D 9. D	Delaware District of Columbia Florida Georgia Hawaii daho	DE DC FL	NN		0	0	0	0	0	0	0
9. D	District of Columbia . Florida	DC FL	N	0	0	0	0	0	0	0	0
	Florida	FL		0	0	0	0	0	0	0	0
10. FI	Georgia Hawaii daho Ilinois		N	0	0	0	0	0	0	0	0
11. G	Hawaiidahollinois	GA	NN.	u	N						0
	daho Ilinois	н	N.	0		0			0	0	0
		ID.	N	0	0	0	0	0	0	0	0
		IL	N	0		0	0	0	0	0	0
15. In	ndiana	IN	N	0	0	0	0	0	0	0	0
	owa	IA	N	0	0	0	0	0	0	0	0
		KS	N	0	0	0	0	0	0	0	0
		KY	N.	0	0	0	0	0	0	0	ļ0
		LA	N	0			0	ū	0	ļ0	ļ
		ME MD	IV NI	 n		 n	 n	ע ה	 n	U	0
		MA	N	n		n	 n	n	n	n	n
		MI	N.	0		0	0	0	0	0	
		MN	N.	0	0	0	0	0	0	0	0
25. M	Mississippi	MS	N	0	0	0	0	0	0	0	0
		MO	N	0	0	0	0	0	0	0	0
		MT	N	0	0	0	0	0	0	0	0
		NE	N	0	0	0	0	0	0	0	0
		NV	N	0	0	0	0	0	0	0	0
	New Hampshire New Jersey		N			0 460,394,513		U		460,394,513	0
	-	NM NM		 n		400,394,313	 N	 N		400,394,313	
		NY	N	0	0	0		0	0	0	0
		NC	N.	0	0	0	0	0	0	0	0
		ND	NN.	0	0	0	0	0	0	0	0
36. O	Ohio	ОН	N	0	0	0	0	0	0	0	0
		OK	N	0	0	0	0	0	0	0	0
		OR	N	0	0	0	0	0	0	0	0
		PA	N	0	0	0	0	0	0	0	0
		RI	NN.	0	0	0 0		0		0	0
		SC SD	NNNNNN	0		0	0 0	 n		0	u
		TN	N.	0	0	0	0	0	0	0	0
		TX	N.	0	0	0	0	0	0	0	0
		UT	N	0	0	0	0	0	0	0	0
		VT	N.	0	0	0	0	0	0	0	0
47. Vi	/irginia		N	0	0	0	0	0	0	0	0
		WA	N	0	0	0	0	0	0	0	0
	West Virginia		N	0	0	0	0	0	0	0	0
	Visconsin		N	0	0	0	0	0	0	0	ļ
	Nyoming American Samoa		NNNNNN	0	0	0 0	0 0	0	0	0	0
	Guam		NNNNNN	0	0	0	0 0	0	0		n
	Puerto Rico		N.	0	0	0	0	0	0	0	0
	J.S. Virgin Islands		N.	0	0	0	0	0	0	0	0
	Northern Mariana			_	_	_		_			
		MP	N.	0	0	0	0	0	0	0	ļ
	Canada Aggregate other	CAN	N.	0	0	0	0	0	0	0	ļ
	alien	ОТ	XXX	0	0	0	0	0	0	0	0
	Subtotal		XXX	0	0	460,394,513	0	0	0	460,394,513	0
(Reporting entity contributions for Em		\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\				•		2		
	Benefit Plans Fotal (Direct Business		XXX XXX	0 0	0	0 460,394,513	0 0	0	0 0	460,394,513	0
	DETAILS OF WRITE		^^^	U	- 0	TOU, 024, J 10	U	U	0	TUU, UUH, U IO	
58001	DETAILS OF WINITE		XXX								
=0000			XXX								
58003			XXX							ļ	
W	Summary of remainin write-ins for Line 58 fr	om	XXX	0	0	0	0	0	0	0	0
58999. To	overflow page Fotals (Lines 58001 tl 58003 plus 58998)(Li above)	hrough	xxx	0	0	0	0	0	0	0	0

⁽a) Active Status Counts:


L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG...

⁰

⁽b) Explanation of basis of allocation by states, premiums by state, etc.

R - Registered - Non-domiciled RRGs...

Q - Qualified - Qualified or accredited reinsurer. ____0



This organizational chart reflects the insurance entity reporting system and identifies the relationship between the ultimate parent and all member insurers.

The ultimate controlling company is a Fortune 7 company with numerous subsidiaries, the majority of which do not interact with the insurance entities.


⁽¹⁾ Insurers/HMO's

Percentages are rounded to the nearest whole percent and based on ownership of voting rights.

Double borders indicate entity has subsidiaries shown on the same page. Bold borders indicate entity has subsidiaries shown on a separate page.

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP


PART 1 - ORGANIZATIONAL CHART



^{*} PHPSNE Parent Corporation is also 45% owned by third parties.

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART



^{*1} PT. Aetna Global Benefits Indonesia is also 20% owned by Suhatsyah Rivai, Aetna's Nominee.

¹ P1. Actna Global Benefits Indonesia is also 20% owned by Sunatsyan Hival, Actna's Nominee.

2 Actna Global Benefits (Middle East) LLC is also 51% is owned by Euro Gulf LLC, Actna's Nominee.

3 Indian Health Organisation Private Limited is 0.019857% owned by Actna Global Benefits (Asia Pacific) and 99.980143% owned by Actna Global Benefits (Singapore) PTE. LTD.

4 PT Asuransi Actna Asia is also 23% owned by PT Asuransi Central Asia.

5 Virtual Home Health Care L.L.C. is also 51% owned by CBD Commercial Brokers LLC, Actna's Nominee


6 Health Care Management Co. Ltd. Is also owned by Actna Global Benefits (Bermuda) Limited (1 share).

7 Actna Health Insurance (Thailand) Public Company Limited is also owned by Actna Global Benefits (Bermuda) Limited (1 share), Mr. Sansanapongpherchar (1 Share), Mr. Jitphasong Itsaraphakded (1 Share): Mrs. Suphee Wattana (1 Share); and Mr. Buncha Tamphragom (1 Share)

^{*8} Aetna Holdings (Thailand) Limited is also 51% owned by Mr. Paiboon Sutantivorakoon plus Aetna Benefits (Bermuda) Limited owns 1 share.


^{*9} Minor Health Enterprise Co. Ltd is is also (1 share) owned by Aetna Global Benefits (Bermuda) Limited

^{*10} Aetna Services (Thailand) Limited is also (1 share) owned by Aetna Global Benefits (Bermuda) Limited and (1 share) owned by Aetna Global Holdings Limited




40.4

ANNUAL STATEMENT FOR THE YEAR 2019 OF THE Aetna Better Health Inc. (a New Jersey corporation)




^{*100%} owned through Aetna's nominees



SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART




^{*1} Aetna ACO Holdings Inc. is owned by Aetna Life Insurance Company (302 shares); Aetna Health Inc. (PA) (198 shares); and Aetna Health Holdings, LLC (1 share).
*2 Innovation Health Holdings, LLC is also 50% owned by Inova Health System Foundation.

^{*3} Texas Health + Aetna Health Insurance Holding Company LLC is also 50% owned by Texas Health Resources.


^{*8} Banner Health and Aetna Health Insurance Holding Company LLC is also 49% owned by Banner Health.

*5 Allina Health and Aetna Insurance Holding Company LLC is also 50% owned by Allina Health.

^{*6} Sutter Health and Aetna Insurance Holding Company LLC is also 50% owned by Sutter Health Plan Products Organization, LLC.



^{*} Aetna Life Insurance Company owns substantially all of the non-managing member interests of Aetna Partners Diversified Fund, LLC.



^{*1} Aetna ACO Holdings Inc. is owned by Aetna Life Insurance Company (302 shares); Aetna Health Inc. (PA) (198 shares); and Aetna Health Holdings, LLC (1 share).

^{*2} Innovation Health Holdings, LLC is also 50% owned by Inova Health System Foundation.

^{*3} Texas Health + Aetna Health Insurance Holding Company LLC is also 50% owned by Texas Health Resources.

^{*4} Banner Health and Aetna Health Insurance Holding Company LLC is also 49% owned by Banner Health.

^{*5} Allina Health and Aetna Insurance Holding Company LLC is also 50% owned by Allina Health.
*6 Sutter Health and Aetna Insurance Holding Company LLC is also 50% owned by Sutter Health Plan Products Organization, LLC.

OVERFLOW PAGE FOR WRITE-INS

NONE

ALPHABETICAL INDEX

ANNUAL STATEMENT BLANK

Analysis of Operations By Lines of Business	7
Assets	2
Cash Flow	
Exhibit 1 - Enrollment By Product Type for Health Business Only	
Exhibit 2 - Accident and Health Premiums Due and Unpaid	
Exhibit 3 - Health Care Receivables	
Exhibit 3A - Analysis of Health Care Receivables Collected and Accrued	20
Exhibit 4 - Claims Unpaid and Incentive Pool, Withhold and Bonus	
Exhibit 5 - Amounts Due From Parent, Subsidiaries and Affiliates	22
Exhibit 6 - Amounts Due To Parent, Subsidiaries and Affiliates	23
Exhibit 7 - Part 1 - Summary of Transactions With Providers	24
Exhibit 7 - Part 2 - Summary of Transactions With Intermediaries	
Exhibit 8 - Furniture, Equipment and Supplies Owned	25
Exhibit of Capital Gains (Losses)	15
Exhibit of Net Investment Income	15
Exhibit of Nonadmitted Assets	
Exhibit of Premiums, Enrollment and Utilization (State Page)	
Five-Year Historical Data	29
General Interrogatories	27
Jurat Page	1
Liabilities, Capital and Surplus	3
Notes To Financial Statements	26
Overflow Page For Write-ins	
Schedule A - Part 1	E01
Schedule A - Part 2	E02
Schedule A - Part 3	
Schedule A - Verification Between Years	SI02
Schedule B - Part 1	E04
Schedule B - Part 2	E05
Schedule B - Part 3	E06
Schedule B - Verification Between Years	SI02
Schedule BA - Part 1	E07
Schedule BA - Part 2	
Schedule BA - Part 3	E09
Schedule BA - Verification Between Years	SI03
Schedule D - Part 1	E10
Schedule D - Part 1A - Section 1	SI05
Schedule D - Part 1A - Section 2	SI08
Schedule D - Part 2 - Section 1	E11
Schedule D - Part 2 - Section 2	E12
Schedule D - Part 3	E13
Schedule D - Part 4	E14
Schedule D - Part 5	E15
Schedule D - Part 6 - Section 1	E16
Schedule D - Part 6 - Section 2	E16
Schedule D - Summary By Country	SI04
Schedule D - Verification Between Years	SI03
Schedule DA - Part 1	E17
Schedule DA - Verification Between Years	SI10
Schedule DB - Part A - Section 1	E18
Schedule DB - Part A - Section 2	E19
Schedule DB - Part A - Verification Between Years	SI11
Schedule DB - Part B - Section 1	E20
Schedule DB - Part B - Section 2	E21
Schedule DB - Part B - Verification Between Years	SI11
Schedule DB - Part C - Section 1	SI12
Schedule DB - Part C - Section 2	SI13
Schedule DB - Part D - Section 1	E22
Schedule DB - Part D - Section 2	E23
Schedule DB - Part E	E24
Schedule DB - Verification	SI14
Schedule DL - Part 1	E25
Schedule DL - Part 2	E26
Schedule E - Part 1 - Cash	E27
Schedule E - Part 2 - Cash Equivalents	E28
Schedule E - Part 2 - Verification Between Years	SI15
Schedule E - Part 3 - Special Deposits	

ANNUAL STATEMENT BLANK (Continued)

Schedule S - Part 1 - Section 2	31
Schedule S - Part 2	32
Schedule S - Part 3 - Section 2	33
Schedule S - Part 4	34
Schedule S - Part 5	35
Schedule S - Part 6	36
Schedule S - Part 7	37
Schedule T - Part 2 - Interstate Compact	
Schedule T - Premiums and Other Considerations	38
Schedule Y - Information Concerning Activities of Insurer Members of a Holding Company Group	40
Schedule Y - Part 1A - Detail of Insurance Holding Company System	41
Schedule Y - Part 2 - Summary of Insurer's Transactions With Any Affiliates	42
Statement of Revenue and Expenses	4
Summary Investment Schedule	SI01
Supplemental Exhibits and Schedules Interrogatories	43
Underwriting and Investment Exhibit - Part 1	8
Underwriting and Investment Exhibit - Part 2	9
Underwriting and Investment Exhibit - Part 2A	10
Underwriting and Investment Exhibit - Part 2B	11
Underwriting and Investment Exhibit - Part 2C	12
Underwriting and Investment Exhibit - Part 2D	13
I Inderwriting and Investment Exhibit - Part 3	14